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ABSTRA CT
Nitric oxide (NO) has been shown to suppress platelet activation, induce
vasodilation, inhibit smooth muscle cell proliferation, and act against infection.
Activated platelets generally have opposite effects from these. They secrete plateletderived growth factor (PDGF), which stimulates smooth muscle growth, serotonin, which
is a platelet agonist, and a number o f agents that promote further platelet aggregation.
However, activated platelets also produce NO through the enzymatic functions o f the
constitutive form o f nitric oxide synthase (NOS). The primary functions o f this
capability are not yet completely understood. Due to its low molecular weight and high
diffusivity, NO is quickly transported from its source to surrounding tissues and medium,
and this characteristic may be instrumental to its function. Understanding the way in
which NO interacts with platelet function could assist in the development o f improved
diagnostic and surgical procedures as well as biomaterials that are resistant to thrombus
formation. Due to the short half-life o f NO in vivo and in vitro, it was desired to use
platelet-derived serotonin and an indicator for NO function. The research objectives for
this project were ( I) to develop mathematical models representing the diffusive transport
o f platelet-derived agonists and inhibitors, (2) to electrochemically measure serotonin
concentration during in vitro aggregation o f platelets to fibrillar collagen with and
without L-N M M A (a NO inhibitor), and (3) to verify platelet aggregation though
histological analysis.

iii
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Presence o f the NOS inhibitor, L-N M M A , did not have a statistical significance
when compared across experiments with fibrillar collagen, which lacked L-N M M A. It
can be inferred from this analysis that a statistically significant change in serotonin
concentration, resulting from platelet activation by collagen, could not be detected when
compared in presence and absence o f the NOS inhibitor L-N M M A . From the research
conducted in this project, many questions have been postulated concerning the primary
role o f NO in platelet function

iv
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CHAPTER 1
INTRO DUCTIO N

1.1 Background and Significance
Maintenance o f homeostasis in human beings and other vertebrates is assisted by
adequate perfusion o f tissue with nutrient-rich blood. During certain pathologies, proper
blood flow to critical tissue is reduced by stenoses or occlusions in the vasculature.
Particularly, i f the heart or brain is starved o f blood for too long, a fatal myocardial
infarction or stroke could result. The two main processes that contribute to occlusive
arterial disease have been shown to be atherosclerosis and thrombus formation.
Throughout life, atherosclerotic deposits infiltrate the initially healthy vasculature o f the
newborn focally, which by middle age affects many individuals with critical thromboses
I . It has been estimated that 1.5 m illion myocardial infarctions occur annually in the

United States, and at least 500,000 o f those infarctions result in sudden death
Past researchers determined the pathogenesis o f occlusive arterial disease is
possibly due to one o f two distinct mechanisms. One mechanism, championed by
Virchow, suggests permeation o f the endothelium and intima by lipid and associated
molecules forms a lipid rich fibrous and smooth muscle plaque locally within the intima
1. However, another hypothesis, developed by Rokitansky and furthered by Duguid,
links the atherosclerotic process w ith thrombosis more closely in that development o f

1
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atherosclerosis is dependent on the presence o f arterial thrombosis 1. Thrombus
formation is a multi-faceted process involving lipids, cytokines, leukocytes, cholesterol,
coagulation proteins, cellular degradation products, and platelets.
Thrombus formation can occur at locations o f atherosclerotic plaque rupture,
damaged endothelium, or intact endothelium. Platelets are a major component o f arterial
thromboses, and they constantly survey the endothelial lining for discontinuities. When
areas o f vascular integrity are disrupted, platelets adhere to the exposed subendothelium
and can recruit adjacent platelets to form a platelet plug over the site o f vascular injury.
Another function o f platelets is initiation o f tissue repair following injury. Platelets can
secrete growth factors and mitogens in order to stimulate the growth o f smooth muscle
cells (SMCs) and other vascular components. Ideally, the platelet thrombus slowly
dissolves away during the process o f vessel repair, but during certain conditions it
continues to grow. A growing thrombus can either proliferate until total occlusion
results, or loose fragments o f the aggregate can break o ff and cause an embolism in a
smaller, distal vessel, thus causing a clinical event.
During certain flows, local hemodynamic forces can alter normal platelet
function. Under conditions o f low shear stress, platelets initially adhere to disrupted
endothelium through interaction with the adhesive subendothelial proteins fibronectin,
vitronectin, and von Willebrand factor (vWF). Adhesion o f platelet membrane receptors
to fibronectin is much faster than adhesion to vWF, but it is a reversible process that
attenuates with increasing shear stress 3. Elevated shear stress causes a conformation
change in the integral platelet glycoprotein Ilb -IIIa (GPIIb-IIIa), resulting in the exposure

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

3

o f more vWF receptors. Due to vWF-mediated adhesion, platelet adhesion to damaged
endothelium also occurs at locations o f high shear stresses.
W ith the increased local velocities found at a stenosis, areas o f high shear stress,
recirculation, and turbulence can occur resulting in enhanced transport o f platelets and
their contents to the vessel lumen. In these areas o f recirculation, platelets have a longer
residence time, causing an increased concentration o f resting and activated platelets.
Increases in shear stress cause erythrocytes to congregate towards the center o f the flow,
thus forcing platelets towards the periphery. This development results in an enhanced
diffusion o f platelets and their contents to the vessel wall. Conditions such as these can
result in platelet adhesion and activation at locations o f intact endothelium.
Atherosclerosis formation with subsequent plaque rupture is similar to this situation.
Platelets and endothelial cells (ECs) have been shown to manufacture and secrete
endothelium-derived relaxation factor (EDRF), a molecule that causes vessel vasodilation
and inhibits platelet activation and aggregation. In the past few years, EDRF had been
deduced to be nitric oxide (NO). With regard to the platelet, NO has the opposite
function o f the other constituents the platelet possesses. Although NO has been shown to
inhibit mitogenesis, act against infection, promote vasodilation, and inhibit coagulation,
researchers still do not know i f the platelet alone can produce the threshold
concentrations required for these physiological actions. Due to the local amplification o f
coagulation factors, platelet deposition, and fibrinogen polymerization to fibrin, the
coagulation cascade is referred to as a positive feedback mechanism. However, platelet
inhibition and the subsequent attenuation o f the coagulation cascade may be regulated or
modulated by local concentrations o f NO. Thus, the interaction between NO and platelet
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activators, such as adenosine diphosphate (ADP), thromboxane A t (T xA 2), and
serotonin, may represent a negative feedback mechanism for platelet activation and
thrombus formation. The positive and negative feedback mechanisms may become
dominant under different circumstances that depend on local concentrations o f agonists
and hence on the diffusion process. Although NO is generated by platelets, its primary
role with respect to the platelet is still unclear.
In the past, it has been suggested that a fundamental role o f the platelet within the
mammalian circulation is host defense against invasion by foreign organisms 4. In some
lower organisms, such as caterpillars, foreign-body responses are initiated by the
adhesion o f hemocytes (primitive leukocytes) to the foreign-body surface, with
subsequent increased aggregation o f neighboring hemocytes 5. The end result is similar
to a hemostatic platelet plug in mammals. This discovery suggests that primary
hemostasis in higher mammals might be a phylogenetic vestige kept from the behavior o f
hemocytes 6.

1.1.1 Throm bosis Formation from Plaque Rupture
The fatty streak is the first noticeable lesion in atherosclerosis formation. In
lesion-prone areas, increased endothelial cell (EC) permeability and activation result in
the transport o f plasma macromolecules into the intima 7. With this flux o f
macromolecules, low-density lipoprotein (LD L) is trapped w ithin the intima and
subsequent oxidative modification o f LD L occurs. Oxidized LD L is then recognized by
the scavenger receptor and endocytosed by monocyte-derived macrophages, which
contribute their enormous oxidative capacity 8. With macrophages present, LDL lipids
are oxidized further, but modification o f the protein portion o f LD L leads to loss o f
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recognition by the scavenger receptor. Changes in receptor recognition result in
macrophage uptake o f LDL by receptors unregulated by the cell’s cholesterol content 8.
This process contributes to foam cell formation, the hallmark o f the arterial fatty streak.
Following fatty streak formation, intimal SMCs proliferate and secrete abundant
collagen rich matrix, forming an elevated intimal lesion termed the mature atherosclerotic
plaque 7. Mature plaque contains a core o f a soft atheromatous material and hard SMCrelated sclerotic tissue. The core is separated from the vascular lumen by a fibrous cap
mainly composed o f collagen, SMCs, and inflamed macrophages. Contents o f the
atheromatous material, commonly called gruel, include crystalline cholesterol,
cholesterol esters, phospholipids, cellular degradation products, and collagen remnants 9.
During the process o f atherogenesis, the endothelium is usually intact, but denuded areas,
related to foam cell infiltration o f the atherosclerotic plaque, also exist. Advanced
plaques causing severe stenoses have a higher fibrous and lower atheromatous content
(less than 20%) than those producing less severe lesions 7,10 g y itself, atherosclerosis
does not induce clinical events, but plaque rupture or dislodgement can trigger a cascade
o f events, possibly culminating to a stroke or myocardial infarction. Figure 1 illustrates
the sequence o f events from the fatty streak to a clinical event.
Since arterial plaques are constantly subjected to mechanical stresses, they are
prone to rupture, and the occurrence o f plaque rupture is unpredictable. Thinning o f the
fibrous cap, located above the atheromatous core, probably precedes plaque rupture. The
thinnest portion o f the fibrous cap is densely populated with macrophages, and is located
at the junction o f the cap with the vessel lumen. Tears, leading to plaque rupture,
commonly develop at this location. Macrophages are capable o f destroying extracellular
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matrix by phagocytosis or by secreting proteolytic enzymes, such as plasminogen
activators and metalloproteinases, which weakens the fibrous cap, predisposing it to
rupture

Fitty Stretk

4
Fibrous
Fsity Streak/

Plaque
\F»tty

Sueak

4
Complex
Fatty Streak/

Plaque
VFatty Streak

Calcification
Plaque

rup ture 4

Thrombosis

4
Clinical Event
Figure 1 - Progression of atherosclerosis from the fatty streak to a clinical event
(Adapted from Berliner, et al 8)
Intrinsic properties o f the fibrous cap determine the vulnerability to rupture, but external
factors expedite the process.
When arterial plaques form a stenosis, velocity gradients within the narrowing
vessel increase, thus creating regions o f elevated shear stress. At locations proximal and
distal to the stenosis, areas o f turbulence, recirculation, and non-uniform flow can
possibly develop. Zones o f recirculation result in longer platelet residence times and an
increase in the transport o f platelets to the vessel wall results. Increased presence o f
activated platelets at the vessel wall can advance the progression o f atherosclerosis
through the secretion o f platelet-derived growth factors and activation o f neighboring
platelets. I f these conditions persist, a platelet-rich thrombus can begin to grow.
Through vWF-mediated adhesion, platelets can adhere to the sub-endothelium o f
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ruptured atherosclerotic vessels, despite the presence high shear stresses. Elevated levels
o f shear stress enhance vWF-mediated adhesion 3.11.
Factors such as shear stress due to a stenosis, sudden pressure changes, external
compression, bending o f eccentric plaques at their edges as a result o f the propagating
pulse wave, or changes in vasomotor tone could tear the thin fibrous cap. Coronary
artery lesions appear to be more susceptible to rupture due to the bending and twisting o f
the artery during each heart contraction, and they are also exposed to two major changes
in flow velocity during systole, compared with a single oscillation for other major
visceral arteries 12,13

sclerotic plaques with a high SMC and collagen content are

fairly resistant to stress, while soft atheromatous plaques with an expanding core o f
extracellular lipid and a thin fibrous cap are unstable and vulnerable 9 Upon plaque
rupture, lipid-rich atheromatous gruel, which is highly thrombogenic, is exposed to
flowing blood. Atheromatous gruel is six-fold more thrombogenic than the collagen-rich
sclerotic component o f the lesion 2. With a highly thrombogenic surface exposed,
thrombotic response to plaque rupture follows. Three major factors that determine the
thrombotic response to plaque rupture are (1) character and extent o f exposed
thrombogenic substrates (2) degree o f stenosis and surface irregularities and (3)
thrombotic-thrombolytic equilibrium at the time o f plaque disruption 9. Plaque growth is
an unpredictable event explained by the occurrence o f plaque rupture with subsequent
hemorrhage into the plaque and/or mural thrombosis resulting in a stepwise plaque
growth 2. Most disrupted plaques are resealed by a small mural thrombus, and only
sometimes does a major occlusive thrombus form

Advanced knowledge on the
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mechanism o f thrombus formation and the inhibitory role o f NO would help to develop
procedures to better treat and diagnose critical thrombus formations at an earlier stage.

1.1.2 Lim itations o f Current Diagnosis
Currently, angiography is the best imaging technique physicians use to quantify
the degree o f coronary arterial stenosis. Although angiography provides good evaluation
o f coronary circulation, it has some critical limitations. Sections o f the coronary artery
that appear normal on the angiogram are used as a reference for the assessment o f
stenotic lesions, but atherosclerosis is a diffuse process that involves vessel segments that
appear geometrically normal. For example, it has been shown that coronary arteries
enlarge in relation to the presence o f atherosclerosis, and the luminal cross-sectional area
may be preserved despite the presence o f vessel disease 12. Thus, physicians can act
only on vessels that appear stenosed or occluded on the angiogram. A vessel lesion,
which reduces the arterial diameter by 50%, is considered borderline severity, but it can
have an atheromatous mass capable o f decreasing the arterial cross sectional area by 75%
12. Giroud et al. found that 78% o f segments responsible for myocardial infarction were
less than 50% stenosed on a previous angiogram, and Ambrose et al. showed the average
degree o f lesion stenosis resulting in myocardial infarction is 48% 10. It has also been
shown in two-thirds o f patients with an acute ischemic syndrome that the responsible
lesion was diagnosed insignificant on a previous angiogram 10. Angiography is a useful
tool for the local severity o f coronary lesions but is limited as a predictor o f future
coronary occlusions. Since coronary artery disease follows a nonlinear course, plaque
rupture and location o f future occlusions are highly unpredictable events 2,12
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1.1.3 Coagulation Cascade
The coagulation cascade is sub-divided into two different pathways, the extrinsic
and intrinsic. Platelets are essential for proper function o f the coagulation cascade. Both
the intrinsic and extrinsic systems share specific coagulation factors with the common
pathway. Figure 2 illustrates the cascade theory o f blood coagulation for hemostasis.
The common pathway begins w ith the conversion o f coagulation factor X to Xa and ends
with fibrin formation. Secondary hemostasis is the term used to designate the
coagulation factors’ role in the hemostatic mechanism.

| Intrinsic Pathway
Contact Collagen
XII

vita

Extrinsic Pathway

HMWK

HMWK

1 ill
(Tissue Factor)
^ ] j a t Tissue Thromboplastin ,
Ca+<"

XIII
Prothrombin ■

Common Pathway

Thrombin
I
Fibrinogen ■

XUIa

Soluble , r Siable
-► F ib rin
►Fibrin
Monomer
Polymer

Figure 2 - Coagulation cascade (Adapted from Turgeon 1$)
According to the cascade theory, each coagulation factor is converted to its active
form by the preceding factor in a series o f biochemical chain reactions ^

initiation o f

coagulation can occur by either the intrinsic or extrinsic pathway, but both pathways
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converge with the common pathway, which converts soluble fibrinogen into an insolublegelatinous fibrin clot. As factor Xa enters the common pathway, factor V, ionic calcium
(Ca2+), and platelet factor 3 (PF3) convert prothrombin (factor II) into thrombin, which is
the active form o f factor II. Association o f factor Xa, factor V, PF3, and Ca2~ on the
platelet membrane surface is called the prothrombinase complex. Activated platelets
support binding o f the IXa/VIIIa and Xa/Va complexes, which functions to localize and
induce coagulant activity at the site o f vessel injury

Once thrombin is produced, it

enters a feedback loop to activate factors V III and V, converts fibrinogen to soluble fibrin
monomers, and helps to stabilize the fibrin monomer by converting factor X III to XHIa,
which crosslinks the fibrin monomers to form a stable fibrin polymer

Fibrin

polymerizes rapidly, forms the primary structure o f the thrombus, traps platelets and
erythrocytes, and binds circulating coagulation and fibrinolytic factors ^ . Within the
platelet-rich fibrin clot, platelets continue to secrete their granule contents and growth
factors, thus contributing to the advancement o f the growing thrombus. Under certain
conditions, an occlusive, platelet-rich thrombus can result.
Upon development o f the fibrin clot, fibrinolysis is also initiated. Fibrinolysis,
the physiological process for dissolving fibrin deposits, is the slow and progressive
enzymatic cleavage o f fibrin to soluble fragments. During any type o f vascular injury,
there is a parallel process o f thrombosis formation and thrombolysis. Therefore, the
ultimate extent o f thrombus formation appears to be dependent upon the dynamic balance
between factors that promote fibrin deposition and platelet activation, and factors that
promote fibrinolytic activity ^ . Initially, early thrombus formations are caused by
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platelet aggregation, but fibrin deposition from the coagulation cascade is responsible for
thrombus stability 9.
Before initiation o f the common pathway via the intrinsic system, platelet
membrane phospholipids are required. A ll factors necessary for fibrin formation within
the intrinsic are in direct contact with or contained in the blood. Initiation o f the intrinsic
pathway is due to exposure to sub-endothelial components such as collagen,
phospholipids, or kallikrein (activated Fletcher factor) activation o f factor X II to Xlla.
Since factor X II is only partially activated by contact with damaged vessel component,
Fletcher factor and high molecular weight kinogen (H M W K ) are required to amplify the
contact activation for the formation o f factor X lla. Contact activation o f the intrinsic
system occurs in the absence o f Ca2+. In the presence o f H M W K, factor X lla transforms
factor X I to XIa. Next, factor XIa converts factor IX to IXa in the presence o f Ca2+.
Following conversion o f factor IX, factor IXa along with the essential cofactor VIII:C in
the presence o f Ca2+ and PF3 (platelet factor 3), a source o f membrane phospholipid,
activates factor X to Xa 16. The macromolecular complex o f factors IXa, VIII:C , X,
PF3, and Ca2+ organizes on the surface membranes o f activated platelets

The platelet

membrane provides a protective environment that expedites the biochemical reactions o f
the intrinsic system without interference from physiological anticoagulants present in the
plasma 15.
The extrinsic system is initiated with the presence o f tissue factor in the blood
circulation. Tissue factor, also known as thromboplastin or factor III, is a membraneassociated glycoprotein (GP) expressed in atherosclerotic plaques by macrophages and
possibly SMC 1?. Under normal conditions, tissue factor is isolated from circulating
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biood, but during severe vasculature trauma, tissue factor leaks into the blood from cells
extrinsic to blood vessels. Oxidized LD L has been shown to induce EC and monocytes
to express increased levels o f tissue factor, and it has been demonstrated by Drake and
colleagues that there is abundant tissue factor in the intima o f atherosclerotic lesions 8. it
is the phospholipid portion o f tissue factor that is required for extrinsic pathway
initiation. After exposure o f tissue factor to the circulation from plaque rupture or
endothelial damage, factor V II is activated to factor V ila in the presence o f tissue factor
and ionized calcium (Ca2 ), also referred to as factor IV. Following activation o f factor
Vila, factor X is activated by Ca2\ factor V ila, and tissue factor to form factor Xa. The
factor X/VIIa/tissue factor complex is regulated by circulating tissue factor pathway
inhibitor

Production o f factor Xa, the final reaction o f the intrinsic and extrinsic

systems, is the starting point for the common pathway. The extrinsic pathway has fewer
steps than the intrinsic system and occurs rapidly, within a matter o f seconds. Thrombin
generated by the extrinsic system can accelerate the intrinsic pathway by enhancement o f
factors V and V III 16

1.2 Platelets and Their Role in H em ostasis
Circulating platelets, also known as thrombocytes, are critical to the coagulation
cascade for thrombus formation. Upon traversing an area o f thrombotic activity, platelets
are in a constant struggle between states o f activation by agonists and inactivation by
inhibitors. Only activated platelets are capable o f thrombin generation from prothrombin.
Before I960, very little research was applied to understanding platelet function, but in
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1962 Bom devised a simple method for studying the response o f platelets to added
agonists by measuring changes in optical density 18.
Platelets are smooth, disc-shaped anuclear cell fragments about 2 to 3 pm across
and shed from the cytoplasm o f mature megakaryocytes. Two-thirds o f the platelets
released circulate in the bloodstream, while the remaining one-third is sequestered in the
spleen at equilibrium with platelets in the blood. In the circulation, they number 130,000
to 400,000 per mm3 o f blood. Platelets have an average lifespan o f approximately ten
days, and their structure can be divided into four distinct areas. These consist o f the
peripheral zone, sol-gel zone, organelle zone, and membrane systems. Figure 3 illustrates
the major platelet divisions.

Mitochondrion

Surface Connected
Canaliculor System

Glycogen
Dense Tubular
System

Platelet
Receptors^ ^ .... ^
(GPItJ and \ > S c . * *
G P lb/m a) A ' - '

BMC
Microlubukes

Lysosomal
Gronule
Microtubules

Dense

a Granule

Granule

Figure 3 - Major divisions and contents of a typical platelet
(From Turgeon
The peripheral zone consists o f the cytoplasmic membrane containing several
glycoproteins surrounded by the glycocalyx, which contains absorbed coagulation
proteins such as factor V, factor V III, and fibrinogen. Integral glycoproteins, which serve
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as receptors for external stimuli, are on the membrane surface as well as on the surface o f
interior membrane channels. Arachidonic acid, a precursor to TxA2, is a major
component o f the phospholipid portion o f the platelet membrane. Major elements o f the
sol-gel zone consist o f microtubules and microfilaments whose primary functions are to
provide a cytoskeleton and contractile system. Increased intracellular Ca2" concentration
induces contraction o f the cytoskeleton during platelet activation.
Beneath the microtubule layer is the organelle zone, composed o f mitochondria,
glycogen particles, dense bodies, alpha granules, and lysosomal granules.
Dense bodies contain ADP, ATP, other nucleotides, phosphate compounds, Ca2\ and
serotonin. ADP stored in the dense bodies is called the non-metabolic pool o f ADP to
distinguish it from the metabolic pool, which is found in the cytoplasm and used for
aerobic metabolism

Cytoplasmic ADP is used as energy for normal platelet

metabolism, whereas the non-metabolic ADP is used during platelet aggregation. Alpha
granules are the most abundant o f the granules and contain vWF, fibrinogen, serotonin,
factor V, factor V II, fibronectin, alphai-antiplasmin, albumin, beta-thromboglobulin,
platelet factor 4, and platelet derived growth factor (PDGF)

Platelets contain two

membrane systems called the open canalicular and dense tubular systems. The open
canalicular is continuous with the platelet membrane, but the dense tubular system, which
serves as a storage site for Ca2\ is not. Both membrane complexes appear to be
important regulators o f intracellular Ca2+ concentration *9
In regard to platelets, thrombus formation takes place through orchestrated events
involving adhesion, activation, primary aggregation, and secondary aggregation. Platelet
adhesion occurs when the endothelial surface is interrupted, exposing substrates such as
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collagen, vWF, fibronectin, vitronectin, and laminin. Initial platelet adherence is
dependent upon plasma vWF binding to the injury site, done to possibly increase local
vWF concentration 11. vWF has been shown to bind to types I and III collagens, and it
has been suggested that it also binds with type IV collagen. vWF present in the
subendothelium can support about 40% o f total platelet adhesion, but its concentration is
not adequate enough for the optimal initiation o f hemostasis 3.11. Glycoprotein lb
(GPIb) is present on the platelet membrane in a tight complex with glycoprotein IX
(GPIX). This GPIb-IX complex (about 25,000 copies per unstimulated platelet) mediates
the initial adhesion o f unstimulated platelets to vWF bound within the subendothelium o f
damaged vessels 20. Other adhesive proteins o f the subendothelium can mediate platelet
adhesion, but under conditions o f high shear flow, vWF appears to be absolutely required
for platelet adhesion 11. It has been shown that Ca2+ is not required for platelet adhesion
to collagen.
The first characteristic o f platelet activation is indicated by transformation from a
discoid shape to a sphere with cytoplasmic projections protruding from the surface. A ll
agonists that induce a platelet response initially cause this morphological change, but
platelet shape change is a reversible process in the presence o f weak agonists. A second
characteristic o f platelet activation is morphological changes within the glycoproteins on
the membrane surface and glycocalyx. These changes cause the platelet to become
sticky, and ligands can then attach to their membrane receptors to further stimulate the
platelet and deliver chemical messages across the platelet membrane

The immediate

effect o f all platelet agonists is similar, for cytoplasmic Ca2+ concentration is increased
due to Ca2+ shift from the dense tubular system resulting in a decrease in cytoplasmic
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cyclic AMP (cAM P), which causes additional Ca2+ mobilization. Four possible
responses related to platelet activation are ( I) shape change (2) aggregation (3) formation
o f TxA2 and (4) granule secretion. Agonists such as ADP and epinephrine are weak
stimulators capable o f inducing the first two responses, while collagen and thrombin are
strong agonists that can potentially lead to all six responses
Secondary aggregation follows primary aggregation and is irreversible and is
mediated by dense granule secretion and TxA2 generation. Platelet response to agonists
is a graded process. As activation continues, contraction and pseudopod formation
progress, constituents o f the organelle zone are redirected towards the center o f the
platelet, and further contraction results in dense body and alpha granule expulsion into
the open canalicular system, which transports contents to the extracellular fluid *6.
Secretion o f dense bodies, alpha granules, and TxA2 amplifies the activation o f adjacent
platelets causing inter-platelet connections to develop via vWF and the G PIIb-IIIa
receptor. Threshold values for platelets are listed in Table I . The exposure o f G PIIb-IIIa
by platelet activation in the presence o f Ca2+ allows fibrinogen as w ell as vWF to form
links between platelets resulting in aggregates 21. Each platelet contains about 40,000
G PIIb-IIIa receptors, the most abundant surface protein that accounts for about 15% o f
the protein mass o f the platelet membrane 22. G PIIb-IIIa also has binding sites for
adhesive proteins such as fibrinogen, fibronectin, and vitronectin and is independent o f
platelet activation, but the binding o f vWF to G PIIb-IIIa occurs only after platelet
activation 11. The number o f fibrinogen molecules binding to G P IIb-IIIa expressed per
platelet on the platelet surface can vary from 25,000 generated by weak activators, to
about 80,000 for strong activators 23.
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Table 1 - Threshold values of platelet agonists
Agonist Concentration
ADP
0.2 pM
1.0 pM
TxA2
0.03 pM
0.20 pM
0.60 pM
Thrombin
0.1 units/mL
Serotonin
5.0 pM

Effect

Reference

Shape change
Reversible aggregation

24
24

Shape change
Reversible aggregation
Irreversible aggregation

24
24
24

Irreversible aggregation

24

Potentiates shape change

25

ADP released from dense granules and neighboring erythrocytes interact with
platelet membrane glycoproteins to activate further G PIIb-IIIa receptors - 1. Further
aggregation o f surrounding platelets is secured through the release arachidonic acid from
the platelet membrane. Arachidonic acid is released from the platelet membrane into the
cytoplasm by the stimulatory activity o f collagen, thrombin, ADP, and serotonin 26.
Through the cyclooxygenase and synthetase enzyme systems in the platelet, arachidonic
acid is converted into TxA2, which promotes further aggregation and is a potent
vasoconstrictor 21. Serotonin in the concentration range o f 0.3 to 0.6 pM potentiates
ADP-induced shape change, but serotonin alone as an activator is ineffective at these
concentrations 25. From recent experimental evidence, it has been suggested that
serotonin dose-dependently enhances platelet activation induced by ADP and thrombin,
thus supporting the idea o f serotonin as a helper agonist 27.
Mitogenic contents are also expelled from the alpha granules at the site o f injury.
Chemokines, mitogens such as PDGF, transforming growth factor beta, and basic
fibroblast growth factor, stimulate the m igration and proliferation o f SMC from the
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media to the intim a and initiates the production o f types I and III collagens, elastin, and
glycoproteins 10>20. j t js probable that many o f the growth factors have a synergistic
role in promoting cell proliferation, w hile others may have an inhibitory effect *.
Platelet transport to the site o f injury is influenced by w all shear stress, and high
shear rates can activate and aggregate platelets in the absence o f exogenous agonists.
Shear rate (sec1) is defined as how fast the adjacent fluent layers are flow ing past one
another, w hile shear stress is the force per unit area (dynes/cm2) the blood exerts on either
blood constituents or the vascular w all in the direction o f flow. In the 1970’s, much
research was performed on platelet function in relation to different shear stresses and
shear rates. It was shown by Munter and Stein that at sufficiently elevated rates o f shear,
the shear rate versus shear stress relation for blood is identical to that o f water, therefore
im plying that blood can be assumed to be a Newtonian fluid under certain conditions 28.
Blood is considered as a Newtonian fluid at shear rates above 1000 sec'1 29. Shear stress
at low magnitudes has no measurable effect on platelets, but there are threshold values at
which measurable changes o f platelet response exist ^

Several experiments have

shown that the shear response and chemical response to agonists are highly synergistic.
For example, Sutera et al., subjected platelets to repeated, short duration pulses o f
exposure to shear stress w ith a one second pause between each pulse. It was observed
that the pulsed exposure resulted in increased platelet aggregation over continuous
exposure for the same total time. This experiment suggests that continuous exposure o f
platelets to stress produces a lower bound to the response o f interm ittent stress * 8. Shear
enhanced m ixing is the mode o f convective transport by which platelets and plasma
proteins interact w ith the vessel w all. Maximum platelet deposition was observed in
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areas o f flow recirculation and minimum in areas o f elevated shear and flow separation
In 1988, a study performed by Aarts et al. demonstrated that as shear rate increased
in a laminar flow, platelets were increasingly expelled from center o f the flow towards
the w all, which resulted in an elevated platelet w all concentration 3 1. Even under
m inim al shear conditions as low as 50 dynes/cm2, changes in platelet morphology and
biochemistry were observed 32. it has been observed that fibrin is more abundant in
thrombi formed under low local velocities because reduced velocity enhances the
accumulation o f activated coagulation factors resulting in thrombin accumulation 29.
Shear-induced aggregation does not require fibrinogen, and shear stress stimulates
arachidonic acid metabolism 18. in severe atherosclerotic vessels, shear stresses may be
as high as 1000 dynes/cm2 29.
Platelets are very complex due to their extrinsic and intrinsic means o f activation,
but certain biochemical agents found in the plasma and manufactured by platelets and the
endothelium act to inhibit platelet activation and aggregation. Antithrom bin III (A T -III),
a circulating plasma protein present in human blood at a concentration o f 4 pM , inhibits
thrombin activity after thrombin generation 24. Due to A T -III activity, thrombin is
unable to convert fibrinogen into fibrin. Just as A T -III attenuates a crucial component o f
the coagulation cascade, nitric oxide (NO) and prostacyclin (PG Ii) generation affect
platelets and the endothelium directly. NO and PGIt act synergistically through cAMP
and cGMP dependent mechanisms 33. NO is produced by the endothelium and platelets,
while PGI2 is produced by the endothelium. Using arachidonic acid from the endothelial
membrane as a precursor, PGI2 is synthesized in a way sim ilar to that o f platelet TxA2
production. Although PGI2 and TxA2 are sim ilar in structure, PGI2 is a vasodilator and
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the terminal guanidinium nitrogen o f the amino acid L-arginine, yielding L-citrulline as
potent inhibitor o f platelet aggregation. Both TxA2 and PGI2 are representatives o f an
important homeostatic mechanism for the regulation o f platelet aggregation and arterial
tone 34 As long as the endothelium is intact and PGI2 is produced and secreted, platelet
aggregation is lim ited in time ^
Platelet and endothelial derived NO is generated by the five-electron oxidation o f
the co-product 35. The entire reaction is catalyzed by the C a'+-dependent form o f the
enzyme NOS. Figure 4 illustrates the mechanism o f NO production in mammals. NO is
a lipophilic molecule that can freely diffuse across cell membranes, and it interacts w ith
many metal and thiol containing molecules. Like PGL, NO is also a potent vasodilator
and inhibitor to platelet aggregation. W ithin the platelet and endothelium, NO interacts
with the soluble guanylate cyclase (SGC) enzyme to induce a conformational change
w ithin the enzyme to stimulate the conversion o f GTP to cGMP 35. Increases in cGMP
result in decreased intracellular Ca2+ levels and the subsequent inhibition o f platelet
activation w ith subendothelial SMC relaxation 37,38 intact endothelium can
spontaneously release NO, resulting in a basal concentration that may inhibit thrombus
formation on healthy vasculature 37. Basal levels o f NO produced by platelets and the
endothelium are generated continuously, but the presence o f platelet agonists occurs only
during periods o f platelet activation.
The endothelium can produce 10- to 40-fold more NO than needed to activate
SGC 39. Combined w ith the NO produced by platelets, toxic levels o f NO do not
accumulate, but NO toxicity is most like ly to result in the diffusion-lim ited reaction o f
NO w ith superoxide (O 2 ) to produce the toxic oxidant peroxynitrite (OONO ) 39 This
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Figure 4 - Overall reaction for the enzymatic production for NO (Adapted from
Knowles et al. 36) A ll NOS studied thus far generate NO for intracellular signaling or
host defense by a 5-electron oxidation o f one o f the guanidino nitrogens o f L-arginine.
L-arginine, O2 , and NADPH are the reactants, NO, L-citrulline, and NADP* are the
products. It has been assumed (but not proven) that the chiral center o f arginine retains
its absolute configuration when converted to citrulline. The boxed O and N atoms show
the origin o f the constituent atoms o f NO.
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reaction (k = 3.7 x 107 M 'se c '1) occurs spontaneously whenever NO and O2 ' are
produced together. Nitrotyrosine, a marker o f OONO' oxidation o f proteins, is noticed
extensively in human atherosclerotic lesions 39. Plasma does not consume NO, but
oxyhemoglobin does, yielding methemoglobin and nitrate as reaction products. The
ratios o f rates o f NO uptake and release for Fe(II)-hemoglobin is 5 to 6 orders o f
magnitude greater than that for oxygen 40, Due to the high reactivity o f NO w ith plasma
constituents, NO must be present in sufficient quantities to counteract the effect o f
platelet agonists. Figure 5 illustrates the possible physiological reactions w ith NO.
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Figure 5 - Biological reactions of nitric oxide
(Adapted from Beckman, et al. 39)
Biological reactions o f NO can be sim plified to three main reactions: (1) its activation o f
SGC (2) its destruction by reaction w ith oxyhemoglobin and (3) its reaction w ith O :' 39.
Mammalian systems express superoxide dismutase (SOD) and catalase activities to
prevent toxicities, but SOD is far less efficient than NO as a scavenger o f O 2 " 39,40
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Superoxide concentration is kept relatively low by SOD, but there is a continual flux o f
O 2 ’ due to aerobic metabolism. About 1 to 5% o f total oxygen inspired is reduced to O 2
39. Due to its short half-life in vivo, NO does not react rapidly w ith most biological
molecules. It does react w ith aqueous oxygen in a second order reaction w ith a half-life
inversely proportional to in itia l NO concentration. Therefore, the half-life o f NO
increases as NO becomes more dilute. Physiological solutions containing NO range from
a maximum o f 4 pM , the amount measured during cerebral ischemia, to a minimum o f 5
nM, the amount needed to activate SGC 39. For example, the ha lf-life o f NO for the 5
nM level is greater than 70 hours (solely reacting w ith O2 ), but in the presence o f O 2 ' and
hemoglobin the h a lf-life is less than a few seconds. In the past few years, much research
has been performed on the functions o f NO in biological systems. The physiological role
o f NO function can be tested through experimentation by providing competitive
inhibitors to NO synthesis. Two compounds readily available from chemical supply
companies are nitro-L-arginine methyl ester hydrochloride (L-N A M E ) and Nc’-m ethyl-Larginine acetate salt (L-N M M A ). Both compounds are fast acting and directly compete
w ith L-arginine binding to NOS.
Knowledge o f the local NO concentration, which minimizes platelet adhesion and
aggregation at sites o f vascular injury, would be useful for the design o f NO-releasing
biomaterials 38. However, many past experiments and mathematical models pertaining
to atherosclerosis and thrombus formation did not incorporate NO as an inhibitor o f
coagulation activity.
Through past experimental studies, much information has been attained on how
platelets react w ith each other and the surfaces w ith which they come in contact.
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Information obtained from these experiments warrants direct implementation into
mathematical models for purposes o f validation and extrapolation. Currently many
models on platelet transport are founded upon chemical kinetics, diffusion, and
hemodynamics. Sorensen et al. have recently developed and published a model based
upon the concentrations o f resting platelets, activated platelets, platelet-released agonists,
platelet-synthesized agonists, prothrombin, thrombin, and A T -III 41. W ith these minimal
components, they were also able to show sim ilar results obtained in vitro by Wagner and
Hubbell 42 Although this model demonstrated good agreement between the
mathematical simulation and experiment, it was based upon a rectangular rather than
cylindrical geometry and did not incorporate the inhibitor NO and agonists such as shear
stress, O i', and serotonin. Analytical measurement o f platelet-derived agonists and
inhibitors are required for proper evaluation o f a mathematical simulation.

1.3 Introduction to Voltam m etrv
Voltammetry encompasses a group o f electroanalytical methods in which
information about a chemical species is derived from the measurement o f current as a
function o f applied potential obtained under conditions that encourage polarization o f a
working electrode 43. H istorically, voltammetry developed from polarography, which
was discovered by the Czechoslovakian chemist Jasroslav Heyrovsky in the early 1920’s
43. Recent advances in microelectrode technology have enhanced the resolution and
sensitivities o f the working electrodes. Use o f voltammetry is lim ited to compounds that
are electrochemically reducible or oxidizable. Voltammetric methods commonly used
for the in vivo and in vitro detection o f biological compounds are cyclic voltammetry
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(C V), chronoamperometry (CA), and differential pulse voltammetry (DPV). Proper
selection o f technique is dependent upon the analyte o f interest. Sub-sections 1.3.1 to
1.3.3 b rie fly review the advantages and disadvantages o f each technique.

1.3.1 C yclic Voltam m etry
In CV, the working electrode’s current response is excited by a triangular
potential waveform (versus reference electrode). From a predetermined starting
potential, the voltage is varied linearly to a maximum potential whereupon the scan
direction is reversed until the potential is restored to the starting potential. This scan
procedure can be repeated several times w ith cycle times ranging from 1 msec to 100
seconds or more. Time between scans is usually 10 times the duration o f the voltage scan
to allow the diffusion layer to relax to its original state 44. Advantage to using CV is the
time resolution that can be obtained from running fast successive scans, allowing insight
to diffusion processes and chemical kinetics. Detection lim itations in CV are due to
interference by current (residual current) other than the electrochemical reaction (faradaic
current) o f interest. Residual current is associated w ith electrode surface properties
(capacitance charging) and increases linearly w ith scan rate, whereas the faradaic current
increases w ith the square root o f scan rate because o f its association w ith diffusion 44.
Detection lim its for CV are on the order o f 50 nM 45.

1.3.2 Chronoamperomfttry
In CA, the working electrode potential is held constant and current is measured as
a function o f time. Excellent temporal resolution is achieved w ith this technique, and the
current measured throughout the measurement interval is proportional to the
concentration o f the species oxidized or reduce. CA is the most sensitive voltammetric
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technique w ith a low-level detection lim it in the sub-nanomolar range 46. The main
disadvantage to this technique is that the origin o f the current can no longer be
discriminated. In a m ultiple species system, the measured current is a superposition o f
any species that is electrolyzed at or below the working electrode potential.

1.3.3 Differential Pulse Voltam m etry
DPV was developed to provide high discrim ination against residual current and is
a hybrid o f CV and CA 44. This technique has a detection lim it around 5 nM, but
sensitivity is achieved through loss o f time resolution. The potential applied to the
working electrode is a linearly increasing pulse train, which is illustrated in Figure 6. In
DPV, the difference in current per pulse is recorded as a function o f a linearly increasing
voltage. Current is measured at two points for each pulse, the first point just before the
application o f the pulse and the second at the end o f the pulse. These sampling points are
chosen to allow for the decay o f the residual current. This technique results in a curve
consisting o f a peak that is directly proportional to concentration.

rr
50 mV
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e
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Figure 6 - Working electrode potential in differential pulse voltammetry
(Adapted from Skoog et al. 43)
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For reversible reactions, the peak potential is approximately equal to the standard
potential for the h a lf reaction (half-wave potentials are useful for discrim ination o f
chemical species). DPV allows concentration discrimination for different species in
solution whose half-wave potentials differ by as little as 40 to 50 mV, whereas classical
and normal pulse techniques require a potential difference o f about 200 mV for resolution
o f m ultiple species 43. Figure 7 compares DPV w ith classical voltammetric techniques.

Differential Poise
Voltammetry

Cyclic
Vottammetry

Potential

Figure 7 - Differential pulse voltammetry compared to cyclic voltammetry
(Adapted from Princeton Applied Research, application note 155)

1.4 Hypothesis and Specific Aims
N itric oxide (NO) has been shown to suppress platelet activation, induce
vasodilation, inhibit smooth muscle cell proliferation, and act against infection.
Activated platelets generally have opposite effects from these. They secrete plateletderived growth factor (PDGF), which stimulates smooth muscle growth; serotonin, which
is a platelet agonist; and a number o f agents that promote further platelet aggregation.
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However, activated platelets also produce NO through the enzymatic functions o f the
constitutive form o f nitric oxide synthase (NOS). The prim ary functions o f this
capability are not yet completely understood. Due to its low molecular weight and high
d iffu sivity, NO is quickly transported from its source to surrounding tissues and medium,
and this characteristic may be instrumental to its function. Understanding the way in
which NO interacts w ith platelet function could assist in the development o f improved
diagnostic and surgical procedures as w ell as biomaterials that are resistant to thrombus
formation. Due to the short half-life o f NO in vivo and in vitro, it is desirable to use
platelet-derived serotonin and an indicator for NO function. Currently, highly sensitive
electrodes are available which allow real-time electrochemical measurement o f serotonin.
The purpose o f this doctoral project is to apply this electrode to an in vitro blood model
to test the follow ing hypothesis.

1.4.1 Hypothesis
Serotonin expelled from activated platelets upon exposure to fib rilla r collagen is
influenced by platelet-derived nitric oxide.

1.4.2 Study O bjectives
The objective o f this study is to develop mathematical simulations and an in vitro
model that represents the concentrations o f platelet agonists and inhibitors using bovine
blood. A ll results w ill be tested for statistical significance against a control.
Specific objectives are as follows:
1. To compare and contrast concentration profiles o f NO and platelet-derived
agonists in a static mathematical simulation
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2. To electrochemically measure serotonin concentration in real-time during in

vitro aggregation o f platelets to fib rilla r collagen in a static situation w ith and
w ithout a NOS inhibitor
3. To verify the degree o f platelet adhesion to fib rilla r collagen in part 2 through
histological analysis
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CHAPTER 2

M ATERIALS AND M ETHODS

2.1 M athem atical M odels
2.1.1 Introduction to M athem atical M odels
Through the use o f mathematical models it was desirable to simulate the static
diffusion o f platelet-derived agonists and inhibitors w ith a transient one-dimensional
analysis. Due to the low concentrations involved, it is d iffic u lt to measure agonist and
inhibitor concentrations near a surface where a platelet thrombus exists 25. Therefore,
the use o f mathematical models is warranted. Agonist and inhibitor release information
from the literature was used as starting parameters for mathematical simulations. Table 2
indicates the species o f interest for the mathematical analysis, their origin, and action.

Table 2 - Species and inhibitors of interest for mathematical modeling
Species
ADP
TxA2

Action
Origin
Activator
Dense granules
Activator
Platelet membrane
Thrombin
Activator
Platelet membrane
Inhibitor
Platelet membrane
NO
Activator
Serotonin
Dense granules
A T -III Inhibits Thrombin
Plasma
02-

Inhibits NO

Plasma

For this dissertation, two separate models were developed for diffusion in a static
medium. The first model simulates agonists and inhibitors generated by the platelet,

30
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whereas the second model simulates agonists released by the platelets. The rate o f
species liberation and the diffusive transport from the surface determine the magnitude o f
the local agonist and inhibitor concentrations 47. Although the governing equations for
each model are sim ilar, boundary and in itia l conditions—and hence solution methods—are
different. Insights gained from the mathematical models allowed for the determination o f
theoretical bounds for agonist and inhibitor concentrations o f interest. The follow ing
section discusses the development o f the governing equations.

2.1.2 M odel Assum ptions
Before development o f the two mathematical models, assumptions were made
concerning the diffusion o f platelet-derived agonists and inhibitors. The models are
designed to simulate the concentration profiles o f agonist and inhibitors follow ing in vitro
platelet activation by collagen in a cylindrical coordinate system. Geometries for both
models consist o f a cylindrical dish whose surface is uniform ly coated w ith collagen.
The dish has a radial dimension o f R, an infinite height o f H, and blood plasma is
assumed to be the medium for species transport. Figure 8 illustrates the physical
parameters for mathematical modeling. The process o f diffusion is assumed to follow
Fick’s first law o f diffusion, which states that a species diffuses as a result o f a
concentration gradient in the direction o f decreasing concentration 48 Mathematically,
this definition relates the mass flux o f a species directly to its concentration gradient by
the follow ing equation where NA is the species flux, DAB is the diffusion coefficient
AT, = - D abV C a

Eq. 1

(assumed to be a constant) o f species A in plasma, and VCA is the concentration gradient.
A transient analysis is assumed, and diffusion occurs prim arily in the axial direction (z-
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coordinate) which is space averaged over the radial and angular coordinates (r and 0).
Any reactions occurring at the collagen surface are assumed to be heterogeneous. For
certain agonists and inhibitors, consumption o f the species occurs in the static plasma
through zero- and first-order chemical kinetics. It is assumed that the plasma is in itia lly
void o f the species o f interest before platelet activation by collagen. Knowing the
assumptions for mathematical modeling, the differential shell balance method can be
employed for development o f the governing partial differential equation. As mentioned
before, model development is sim ilar for both the agonist and inhibitor release and
agonist generation models.

Plasma

Species diffusion

Collagen
R

Figure 8 - Physical parameters for mathematical model development

2.1.3 G eneral M odel Developm ent
An appropriate differential shell was chosen based on the assumptions in the preceding
section. Performing a conservation mass balance over a differential shell o f plasma
develops the governing equation. The mass balance states that the resulting
concentration o f an agonist or inhibitor w ithin the differential plasma shell is equal to the
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difference between the diffusive flux o f the species into the shell, and the sum o f the
species lost due to consumption or diffusive flux out o f the shell. Figure 9 illustrates the
mass fluxes and consumption occurring w ithin the plasma shell. In this figure, NA

*

N A « M (i + A i>
Plasma
Shell

Az J

I rate of species I
I accumulation I

I rate of
I I rate of
I species in I I species out I

Figure 9 - Species mass balance for a differential shell with consumption
represents the mass flux o f species A and - k nCn represents the homogeneous
consumption reaction o f order n, where k is the reaction rate constant. The reaction term
can be transformed into a first-order reaction by assuming constant O 2 ' and A T -III
concentrations.
When the species are related as mass fluxes to the finite differential shell a mathematical
expression (Eq. 2) is achieved that represents the diffusive transport.

= N A!zR'- - N ^ z R 1 - t e { z R ! > „ C ; Eq. 2

A z(*S !

at
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This expression is transformed into a partial differential (Eq. 3) equation when the
dimensions o f the shell become infinitesim ally small and Fick’s law is applied.

Eq.3
Upon integration o f the resulting partial differential equation and application o f boundary
and in itia l conditions, a particular solution to the diffusion problem is obtained. The
resulting solution for the platelet agonists and inhibitors is dependent upon whether they
are generated on the platelet surface or released by the dense granules.

L lA S o lu tio n to Agonist and Inhibitor G eneration Model
Using Equation 3, and applying the proper boundary and initial conditions, the
particular solution o f the agonist generation models is developed. W ith species
generation, it is assumed that generation occurs w ithin or on the platelet phospholipid
membrane. The two boundary conditions for this model are: (1) a constant
heterogeneous flux (AT) o f species at the collagen surface and (2) species concentration
approaches zero at an infinite distance away from the collagen surface. An infinite
distance was assumed to be on the order o f a few m illimeters distance, a valid assumption
due to the platelets small size. The in itia l condition states that species concentration is
equal to zero at all distances in itia lly. Equations 4 through 6 below express these
conditions mathematically.

Eq. 4

c .<0»oo) = °

Eq. 5

C ,(0 ,z ) = 0

Eq. 6

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

35

Agonists generated that are o f interest for this model are thrombin and TxA2, while the
inhibitor o f interest that is generated is NO. Each o f the species generated by the platelet
is homogeneously consumed in the plasma. A Laplace transform approach through the
application o f equations 4 through 6 was used to find the particular solution for equation
3, which is represented by equation 7 below. The fu ll solution to the problem is shown in
appendix A.

Eq. 7

2.1.5 Solution to Agonist Release M odel
Solution to the agonist release model requires different boundary and initia l
conditions than the generation model. W ith agonist release, it is assumed that platelets
release their granule contents immediately upon activation by collagen. The two
boundary conditions for this model are (1) the flux at the collagen surface is zero for all
time and (2) agonist concentration approaches zero at an infinite distance away from the
collagen surface. In itia l condition states that at time equal to zero, there is an impulse
(represented by the Dirac delta function, 8(z)) o f agonist release (nio) occurring only at
the collagen surface. This condition implies that released agonists are in itia lly
concentrated in an infinitesim al zone near the surface o f adhered platelets. Equations 8
through 10 express these conditions mathematically.

CA( t , oo) = 0

Eq. 9

CA(0,z) = S{z)m0

Eq. 10
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Released agonists o f interest for this model are serotonin and ADP. These are
relatively stable and are therefore not consumed in the plasma. M odification to the
governing equation is achieved by setting the consumption term equal to zero. A Fourier
transform solution through the applications o f equations 8 through 10 was used to find
the particular solution, represented by Equation 11 below. The fu ll solution to the
problem is shown in Appendix B.

Eq. 11

2.2 Preparation of Serotonin Sensor
2.2.1 Sensor Design and Fabrication
The sensor was designed to be sensitive to low concentrations o f serotonin in a
small volume o f space. This type o f sensor was carbon-fiber based and mounted on the
tip o f a pulled glass capillary tube for the purpose o f serotonin detection in vitro.
Production o f the sensor is achieved w ith a four-step process. The first step involves the
pulling o f a glass capillary over a Bunsen burner flame.
A 50 mm glass capillary tube (Kim ax® , Kim ble Products) w ith a 1.5 mm internal
diameter was used to create a tapered-tip glass capillary. The glass capillary was held
between the thumb and forefinger o f each hand, and the center o f the capillary was
slow ly lowered onto the tip o f the Bunsen flame (not directly w ithin the flame). Holding
the capillary tube in tension over the heat o f the flame allowed the glass capillary to be
pulled into two separate tapered-tip capillaries w ith sealed tips. Once the glass capillary
cooled to room temperature, a razor blade was used to cut an opening on the narrowest
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part o f the tapered tips. The resulting tip was measured w ith a light microscope (Nikon®
Instruments) to be approximately 200 pm. Then, the freshly cut tips were quickly passed
through the Bunsen flame (fire-polished) to smooth the sharp glass edges that resulted
from cutting the tip.
The second step involved mounting the carbon fibers into the finished glass
capillary tubes. Medical-grade carbon fibers (Amoco Performance Products, Greenville,
SC, 6 pm diameter, 12 Q cm) were used as the sensing element for the serotonin sensor.
The carbon fibers were shipped braided in a spool and had to be separated into individual
fibers. Under sterile conditions using latex gloves, a 3-inch segment o f braided fibers
were cut from the spool and teased apart w ith a sterile probe. Once two individual fibers
were isolated from the braid, they were gently twisted together to form a double fiber. It
should be noted that although the carbon fibers are very strong, they are extremely brittle.
Great care should be exercised during the entire fabrication process. Next, the twisted
double fiber is loaded and gently advanced through the large diameter end o f the tapered
glass capillary until the double fiber can be seen protruding through the tapered end.
Figure 10 illustrates the main parts o f the sensor fabrication process.
The third step o f the fabrication process involved creating an electrical contact for
interfacing the transducer w ith supporting instrumentation. One end o f a 1 to 2 m
spooled bare copper wire (AW G 18, ARCOR®, Glenview, IL ) was placed in a vise and
pulled to straighten out any curvature or kinks. The straightened copper wire was then
cut into 75 mm lengths and polished w ith fine-grain sandpaper to help increase the
sensitivity and conductivity o f the finished sensor. Then the polished 75 mm length o f
straight copper wire was covered entirely w ith a thin coat o f conductive silver-epoxy (A I
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Carbon fibers

Pulled
glass
capillary
Inserted
carbon fibers

Cu wire and
silver epoxy

Beeswax

Figure 10 - General fabrication process of serotonin sensor
Technology, Lawrenceville, NJ) and was gently brought into contact w ith the carbon
fiber protruding from the large diameter end o f the tapered glass capillary. W ith the
carbon fiber adhered tip. The fourth step involved the finishing procedure for the
electrodes. A fter inserting the copper rod, the electrodes were baked in an oven at 100
degrees C for an hour to allow proper drying and curing o f the silver epoxy. The baked
electrodes were allowed to cool to room temperature, and then the protruding carbon
fibers were trimmed w ith a new razor blade to a final length o f 2.0 mm. Next, touching a
drop o f molten beeswax to the opening o f the tapered tip, where the carbon fiber
protrudes, sealed the tip o f the glass capillary. A fter cooling, excess beeswax (a high
molecular-weight ester) was removed by saponification (immersion in 0.1 M NaOH
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overnight), followed by rinsing w ith distilled water. A fter rinsing, the finished electrodes
were stored dry in a dust-free environment by inserting the copper conductor into a block
o f cork and covering w ith a 200 mL flask.

2.2.2 Supporting Instrum entation and O peration
A Princeton Applied Research model 263A potentiostat/galvonostat (EG&G
Instruments, Inc., Tennessee), interfaced to a PC-compatible Pentium computer through a
GPIB port running the m270 electrochemical analysis software package (Princeton
Applied Research), was used for the am plification and pre-processing o f the electrode
signal. A ll electrochemical measurements incorporated a three-electrode system
consisting o f a working electrode (carbon fiber sensor), a platinum-wire counter
electrode, and a reference electrode. A ll three electrodes were in close proxim ity o f (5 to
10 mm) o f each other, but not touching.
The reference electrode (see figure 11) consisted o f an isolated silver-silver
chloride (A g/A gC l) electrode (Ag/AgC l electrode obtained from W orld Precision
Instruments). Isolation was achieved via a potassium chloride (KC1) salt bridge. This
electrode was fabricated by the follow ing procedure w ith reagents purchased from Sigma.
A 4% agarose gel was prepared by dissolving agarose into KC1 (40 mg/mL). The
mixture was heated in a double boiler until all agarose was dissolved. Once it was
dissolved, a plastic transfer pipette was attached to the end o f a 1.0-inch length o f Tygon
tubing (1.5mm inside diameter). The end o f the tubing was immersed into the dissolved
agarose solution, and slight suction was applied to fill the volume o f the tubing w ith the
resulting agarose gel. A fter cooling, the agarose gel solidified and was ready for
insertion into the Ag/AgCl electrode. Electrical contact between the KC1 salt bridge and
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To 263A
potentiostat

Saturated
KC1 —

KC1 salt
bridge

Figure 11 - Isolated Ag/AgCl reference electrode
Ag/AgC l electrode was achieved through a saturated KC1 solution. When not in use, the
reference electrode’s tip was kept immersed in saturated K.C1 at room temperature to keep
from drying. Reference electrode life was approximately three months i f proper care was
given.
D ifferential pulse voltammetry (DPV) was the method o f choice for determination
o f serotonin concentrations. Figure 12 illustrates the parameters used for the DPV
analysis. For calibration and experimental use, the voltage sweep for the DPV procedure
was isolated to encompass the range where serotonin is oxidized and the range set from
300 mV to 700 mV w ith a scan rate and scan increment o f 10 mV/sec and 3 mV
respectively. The pulsing parameters were a pulse height o f 25 mV, a step/drop time o f
100 msec, and a pulse w idth o f 50 msec. Importance o f the pulse shape was explained in
section 1.3.3 o f chapter I.
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700 mV

50 msec

25 mV
100 msec
300 mV
Time
Figure 12 - Differential pulse voltammetry parameters for serotonin
detection

2.3 M icroelectrode C alibration and Analysis
2.3.1 Preparation o f Phosphate Buffer
A phosphate-buffered saline (PBS) solution was the electrolytic medium for the
calibration procedure. The basis o f the PBS solution consisted o f PBS tablets obtained
from Sigma. To create 200 m l o f PBS, one tablet was dissolved into 200 mL o f distilled
water. To match the pH and chemical environment the probe would be in contact w ith
during experimental procedures, the PBS solution was made according to the procedure
used by V o lf et al. This solution was sim ilar to a Tyrode buffer containing 137 m M o f
NaCl, 2.7 mM o f K C 1,11.9 mM ofN aH C O j, 1.0 mM o f M gCl2, 0.42 mM o f NaH2P04,
5.5 mM o f D-glucose, and 1.0 mM o f CaCh ^9. The buffer was also loaded w ith L-
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arginine to create a final concentration o f 1 mM. A ll reagents used were purchased from
Sigma, and solution pH was adjusted to 7.4 by adding drops o f either 0.1 M HCl or 0.1 M
NaOH. Final solution pH was verified w ith pH sensitive paper. When not in use, the
PBS solution was kept refrigerated and slow ly heated to room temperature prior to use.
Before each use, the pH was re-tested to ensure proper range (7.4 ± 0.2).

2.3.2 Electrochem ical Pre-Treatm ent
The surfaces o f graphitic materials such as carbon fibers are very complex.
Figure 13 illustrates the surface o f a typical graphitic carbon surface. A t the atomic level,
graphite has a uniform structure (basal plane) and is almost electrochemically inert in
aqueous solution. It appears that most electron transfer reactions occur at the edge o f the
basal plane, which is often covered w ith a large number o f oxygen-containing function
groups such as phenols, carbonyls, carboxylic acids, and quinones 44 [n 1980, Gonon
and coworkers showed that an increased response from carbon fibers could be achieved
through the electrochemical oxidation o f the cylindrical surface 50. Following treatment
voltammograms appear sharper and the detection lim it o f some chemical species can
approach 5 nM 51.
Using the pre-treatment procedure outlined by Lantoine et al., electrodes were
conditioned w ith three electrochemical processes to ensure electrode stability and a
reproducible baseline. They were treated in PBS solution by ( I) applying an alternating
potential frequency (50 Hz) o f a triangular waveform for 20 seconds w ith the lower and
upper potentials o f the waveform being 0 V and 2.9 V respectively (2) applying a
constant negative potential o f-0.8 V for 5 seconds and (3) applying a constant positive
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potential o f 1.5 V for 5 seconds 52. Procedures for electrode conditioning were
programmed into the model

SurFoee Corbon

SurFoee

F u n c t i o n o I 1 1 ■es
PhenoI
Co rb o nyI

Bulk
Corbon

Oumones

Figure 13 - Graphitic oxide surface structures found on carbon materials
(from Kawagoe, et al. 44)
263A voltammetric analyzer using the m270 software. Electrode conditioning was
conducted before any calibration or experimental use.

2.3.3 Creation o f Serotonin Standards
Serotonin (creatine sulphate complex, M W o f 387.4, H-7752, 1 gm) was
purchased from Sigma. Although serotonin is relatively stable at physiological pH and
temperature, Sigma recommends that new standards be created before any use. In itia lly,
a 400 pM solution o f serotonin was created (6.2 mg o f serotonin into 40 mL PBS). This
solution was then diluted w ith PBS to achieve 10 mL o f a 40 pM working standard (1 mL
o f 400 pM serotonin solution into 9 mL o f PBS). Between uses, the working standard
was kept in the refrigerator or in an ice bath. To achieve the desired concentration o f
serotonin, m icroliter aliquots were injected w ith a Hamilton micro-syringe into a 35 mm
polystyrene Petri dish containing 5 m L o f PBS. For calibration purposes, the domains o f
serotonin concentrations were between 4 and 140 nM. Table 3 indicates the volume o f
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serotonin to inject into 5 mL o f PBS to achieve a controlled concentration o f serotonin
for sensor calibration.

Table 3 - Creation of S m L serotonin standards for calibration
Volume of 40 pM Required (p L ) Serotonin (nM)
0.5
4.0
1.0
8.0
3.0
24.0
8.0
64.0
18.0
144.0

2.3.4 Calibration Protocol
Electrode calibrations were necessary for finding a relationship between measured
current and serotonin concentration. As mentioned before, a three-electrode system was
implemented for serotonin detection. Sterile polystyrene tissue-culture dishes (35 mm x
10 mm, Com ing) were the electrochemical cell for the calibration procedure. A new dish
fille d w ith fresh PBS was used for each electrode calibrated. Before the electrode system
was placed into position, each electrode was rinsed three times w ith distilled water for the
removal o f any surface particles. The isolated reference was secured by a clamp to
position just below the PBS surface, while the carbon fiber and platinum counter
electrodes were secured w ith a micromanipulator above. In itia lly, the counter and
working electrodes were held in a position above the PBS surface. Before execution o f
the DPV protocol, the counter and working electrodes were slow ly lowered w ith the
micromanipulator to a position just below the PBS surface. Figure 14 illustrates the
physical setup for the calibration procedure. Calibration procedures were performed
under a constant stir condition using a magnetic stirrer bar to ensure proper m ixing o f the
PBS w ith serotonin.
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Figure 14 - Electrochemical cell used for electrode calibration
A ll probes were calibrated w ith serotonin concentrations o f 0 ,4 , 8, 24.64, and
144 nM respectively. A serotonin concentration o f zero represented a baseline
measurement taken solely in PBS. For each serotonin concentration, three repeated
measures were performed, and the raw data acquired by the potentiostat was saved as an
ASC II text file and stored on the computer’s hard drive for post-processing. Including
the baseline measurements, a total o f 18 files were saved for each probe calibrated (3
repeated measures, 6 different concentrations). Raw data consisted o f current in nA
versus scan potential in mV.

2.3.5 Analysis o f Sensor Data
Raw data obtained from the DPV procedure were post-processed using Labview
5.1 software (National Instruments, Austin). A Labview virtual instrument was
developed to read the raw DPV data for an entire electrode calibration, calculate the
changes in signal currents attributed to serotonin oxidation occurring at 550 ± 50 mV,
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and save the processed values as a function o f calibration concentration w ithin a
M icrosoft Excel spreadsheet file. Change in current was calculated as the magnitude o f
the difference between baseline and oxidation peak.
Due to inherent Gaussian noise in the raw data, oxidation peaks were modeled as
fourth-order polynomials, w ith the peaks considered to be the relative minima o f the
functions. Baseline levels were determined to be the average o f five data points before
baseline deflection caused by serotonin oxidation. Figure 15 illustrates how the analysis
is performed on a single raw data file. Important parameters saved to the spreadsheet file
consisted o f the o f magnitude o f current difference between peak and baseline, relative
minima potential, relative minima current value, mean baseline current value, the
polynomial coefficients o f the regression, and the corresponding serotonin concentration.
Once an electrode’s data were processed for all serotonin standards o f interest, a power
law regression (Equation 12) was performed in Excel on the scatter plot o f the repeated
measures o f current difference (mean ± standard deviation) versus serotonin
concentration.
y (x ) = Axc

Eq. 12

A power law relationship allowed mapping from current value to concentration and vice
versa.
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Figure 15 - Example of raw data analysis by Labview

2.4 Testing o f Electrode in Blood
2.4.1 Blood Collection and Processing
Variants o f blood were tested to establish electrode response to a biological
environment. A ll blood used was from the same bovine source and was collected by
animal-care professionals at the Louisiana Tech University farm. Experiments in this
dissertation used whole blood, platelet-rich plasma (PRP), platelet-poor plasma (PPP),
and dilute PRP. Whole blood was collected from the jugular vein into a 60 cc syringe
(Cole Palmer) using a 16-gauge needle. Before blood collection, a 0.129 M sodium
citrate solution (Sigma) was pre-loaded into the syringe to be used as the anticoagulant
(ratio o f blood to anticoagulant was 9:1). The needle was allowed to puncture the vein
and blood was allowed to flow freely for three seconds before the syringe was connected
to the needle. Once connected, the syringe barrel was slow ly drawn back to the desired
sample volume. Following blood collection, the needle was removed and the syringe
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gently inverted four times to ensure proper m ixing o f the blood and anticoagulant. The
syringe was kept at ambient temperature until experimental use or further processing. A ll
experiments using whole blood were conducted w ithin 30 minutes o f blood collection.
Protocols used for PRP and PPP generation were outlined in the clinical hematology text
written by Corriveau and Fritsma 53. PRP was created by placing the citrated whole
blood in a centrifuge and spun at a force o f 50 x g for 30 minutes at ambient temperature.
A fter centrifugation, the PRP (top supernatant) was transferred into a sealed plastic vial
w ith a sterile plastic pipette.
PPP was generated from the remaining supernatant by centrifuging at 2000 x g for
10 minutes at ambient temperature. Again, the PPP (top supernatant) was transferred into
a sealed plastic vile w ith a sterile plastic pipette. Dilute PRP was created through the re
suspension o f PRP w ith PBS. PRP was diluted w ith enough PBS to achieve the original
blood volume present before centrifugation. For example, i f 100 mL o f citrated whole
blood produced 10 mL o f PRP, 90 mL o f PBS was added to the PRP. A ll experiments
conducted using PPP, PRP, or dilute PRP were conducted in fewer than 4 hours as
recommended by Corriveau and Fritsma 53.

2.4.2 Uric Acid Interference Study
This study was conducted to establish whether or not uric acid interfered w ith the
detection o f serotonin in PBS. Electrodes were calibrated w ith subsequent additions o f
serotonin as before, but the in itia l 5 m L o f PBS medium contained a 200 pM
concentration o f uric acid (Sigma). DPV was implemented to establish the potential at
which 200 pM uric acid is oxidized and corresponding change o f baseline current.
Follow ing the electrode calibration w ith serotonin, 0.2 units o f uricase enzyme (Sigma)
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was added to the PBS/UA medium, and subsequent electrode measurements recorded the
effect o f uricase.

2.4.3 Serotonin Calibrations in Blood Variants
Serotonin calibrations were conducted in whole blood, PPP/PRP, and dilute PRP
w ith 0.2 units o f uricase enzyme. Electrode sensitivity to serotonin and optimal medium
for measurement was established through this experiment.

2.5 Static Study to M easure Serotonin Release from Platelets
2.5.1 Preparation o f Platelet Suspensions
This study determined the effect that platelet-derived NO has on serotonin release
due to activation by fib rilla r collagen. Four different experimental situations were
performed for this study (listed in Table 4). Dilute PRP was created in the same
procedure as mentioned before from 100 mL o f bovine blood. Experiments 1 and 3 serve
as controls for experiments 2 and 4 respectively. Before experimentation, the 100 mL o f
dilute PRP was equally divided into two 50 mL aliquots, and treated w ith uricase enzyme
(0.1 units per 5 mL o f dilute PRP). Thirty m illilite rs o f one aliquot were pre-treated for

Table 4 - List of the four different experimental situations
Experiment #

Dish Surface

Medium

1

Bare surface

PBS solution

2

Collagen surface

PBS solution

3

Bare surface

PBS solution w ith Im M L-N M M A

4

Collagen surface

PBS solution w ith Im M L-N M M A

five minutes before experimentation w ith 1 mM N°-m ethyl-L-arginine acetate salt (LN M M A , Sigma). L-N M M A inhibits NO through competitive inhibition o f all three
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isoforms o f NOS. Diluted platelet suspensions were used w ith four hours o f PRP
generation. Dishes were coated w ith fib rilla r collagen on the night before the
experiment.

2,5,2 Preparation o f Fibrillar Collagen Film
Twelve m illilite rs o f chilled Vitrogen collagen (Cohesion Co., Inc.) was mixed
w ith 1.5 mL o f lOx phosphate buffered saline (Sigma) and 0.1 M NaOH. Solution pH
was adjusted to 7.4 ± 0.2 by the addition o f a few drops o f either 0.1 M HC1 or 0.1 M
NaOH. The final solution pH was verified w ith pH paper. Before use, the mixture
(isotonic collagen solution) was stored in a refrigerator. To coat the surface o f the tissue
culture dishes, 1 mL o f the isotonic collagen solution was added to dish surfaces. This
volume covered the surface o f the dish to a height o f 1.5 to 2 mm. Each dish was then
gently oscillated to ensure even distribution o f the collagen solution throughout the
surface o f the dish. Then, each dish was covered and incubated for one hour at 37
degrees C to promote gelation. The dishes were then left uncovered in a laminar flow
hood overnight or until dry. A fter drying, the collagen film was gently rinsed w ith
distilled water to remove salts and to also rehydrate the film . Once complete, the film
was used immediately or allowed to dry again for future use. A fter drying was achieved
for the second time, unused dishes were refrigerated for future use.
Validation o f the fib rilla r collagen coating was achieved through staining with
eosin. The collagen-coated dish was rehydrated w ith distilled water for 5 minutes. Next,
the water was siphoned o ff and replaced w ith 10% buffered form alin solution for
fixation. Follow ing fixation, the dish was drained o f form alin and rehydrated in water for
1 minute, 50% ethanol (ETOH) for 2 minutes, 70% ETOH for 2 minutes, 90% ETOH
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w ith eosin for 1 minute, 95% ETOH for I minute, and 100 ETOH for 1 minute. Next, the
dish was placed in the clearing agents, Histoclear II and Histoclear I, for 2 and 5 minutes
respectively. The dish was immediately examined under a light microscope (Nikon) at a
magnification o f 100.

2.5.3 Serotonin M easurem ents in Dilute PRP
The working and counter electrodes were electrically isolated and attached to
each other w ith a m ild adhesive in a parallel fashion w ith an average tip separation o f 3
mm. A support arm o f the micromanipulator held the electrode system at an angle o f 30
degrees relative to the horizontal. The micromanipulator lowered the counter and
working electrode system to a position above the dish surface (close to the surface, but
not touching). Distance from dish surface to the electrode neck was approximately 1
mm. Another support arm secured the isolated reference electrode close to edge o f the
dish. Prior to DPV measurement, 5 mL o f dilute PRP (with or without L-N M M A ) was
pipetted into the tissue culture dish. The physical setup described above was
incorporated for both the coated and uncoated dishes and is illustrated in Figure 16.

Reference
Electrode

["- |

1

Counter
Electrode

Dilute
PRP J r \ a

ar

Working
Electrode
a = angle from surface

Collagen Surface
Figure 16 - Physical setup for serotonin measurement from dilute PRP
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For each experimental situation, four replicates (N = 4) were conducted w ith three
repeated measures each. Fresh calibrated working electrodes were used for each replicate
in the study. Analysis o f DPV data was performed as described before and
corresponding serotonin concentrations were quantified through each electrode’s power
law regression. A t the completion o f a replicate, the dish was promptly removed from
the electrode system, drained o f contents, gently rinsed w ith distilled water, and fixed
w ith 10% buffered formalin. The dish was then set aside for future histological analysis.

2.5.4 H istological Preparation and Analysis
A fter electrochemical analysis, each tissue culture dish was fluorescently stained
w ith acridine orange (Sigma). Acridine orange was mixed w ith distilled water to a final
concentration o f 0.1 g /1 0 0 mL 54 Procedure for acridine orange staining is as follows:
the fixated tissue culture dishes were rehydrated in distilled water for 2 minutes and then
rinsed in running distilled water for 5 minutes. Next, the dishes were stained in the
acridine orange solution for 2 minutes and then rinsed in distilled water again for 30
seconds. Dishes were then dehydrated in 95 and 100 % ETOH for 1 and 3 minutes
respectively. Clearing o f excess stain was achieved through immersion in Histoclear II
for 3 minutes. A fter staining, the dishes were covered, wrapped in fo il to avoid exposure
to light, and placed in a refrigerator until microscopic analysis could be performed.
Acridine orange fluoresces w ith a mercury lamp using an excitation filte r o f 450 to 490
nm and a barrier filte r o f 520 nm 55.
Each stained dish was examined under a light microscope w ith ultraviolet
capabilities (N ikon) that was integrated w ith a digital camera (MS 120, Kodak) connected
to a Pentium PC running Photoshop 5.5 (Adobe) software. Images acquired from the
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microscope system were imported into Photoshop and saved as high-quality JPEG image
files. Five random locations in each dish were imaged at magnifications o f 40, 100, and
400 in both the light and ultraviolet fields. A calibration slide, possessing a scale
resolution o f 10 pm, was imaged in the light field at the different magnifications levels.
Saved images o f the calibration slide were used to accurately determine a length scale o f
the dish images.
Visual analyses o f the resulting images from the static study were used to quantify
platelet adherence. Ultraviolet images (from experiments 2 and 4) taken at
magnifications o f 40 and 100 were analyzed in Photoshop by counting the number o f
platelet aggregates adhered to the collagen surface. Analysis o f the surface area covered
by the platelet aggregates was performed w ith the follow ing method. A ll images o f
interest were converted to grayscale. Through image processing capabilities w ithin
Photoshop software, a histogram o f pixel brightness level was performed on each
grayscale image. The range o f brightness levels was from 0 to 255 w ith a bin resolution
o f unity. A ll image background levels were tested, and the threshold level for aggregate
determination was set to 200. Measured value from the histogram was the number o f
pixels in the greater than or equal to a brightness level o f 200. The ratio o f measured
value to total pixels present was a measure o f percent surface area covered by platelet
aggregates.

2.5.5 Statistical Procedures
The change o f current for each measurement performed w ith DPV was mapped
back to a serotonin concentration using the electrode’s power law regression to solve for
the concentration level (Equation 13). A and C are regression coefficients, x is the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

54

serotonin concentration in nM , and y is the measured current difference in nA. Statistics
were performed on these calculated values o f serotonin concentrations. In itia lly, a single-

x (y ) = e c

Eq.13

factor analysis o f variance (A N O V A ) was performed using the different experimental
procedures as treatment levels (a = 0.05). Tukey’s test was performed for m ultiple
comparisons across the four different treatment levels. For protection against an inflated
error mean square, a two-factor A N O VA was also performed w ith the two factors defined
as experiment type and replicate number (a = 0.05). Tukey’s test was conducted for
m ultiple comparisons between experiment types. Two-tail / tests (a = 0.05) were
performed on the platelet aggregate counts and percent surface area data obtained from
the Photoshop analysis.
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CHAPTER 3

R ESULTS

3.1 M athem atical M odeling
3.1.1 A gonist and Inhibitor G eneration M odel
Development o f the agonist and inhibitor generation model assumed
homogeneous species consumption in the plasma. TxA2 is hydrolyzed to TxB2
(thromboxane B2) by a first-order reaction, thrombin is inhibited by A T -III through a
second-order reaction, and NO is also consumed through a second-order reaction with
superoxide. Although the reactions involving NO and thrombin are second-order
kinetics, pseudo first-order reaction rates may be calculated i f plasma concentrations o f
A T -III and 02' are assumed to be constant, 24. Plasma concentrations o f A T -III and 0 : ‘
were assumed to be 4 pM and 0.6 nM respectively. Table 5 shows the model parameters
for TxA2, thrombin, and NO transport w ith calculated surface flux and first order

Table 5 - Parameters for agonist and inhibitor generation model
Species

Dab (cm2/s)
TxA2
2.14 x 10'6
Thrombin 4.16 x 10‘7
NO

3.30 x I O’5

K (surface flux)

Inhibitor

2.3 x 10'7 pmol/(cm 2-s)

Hydrolysis

1.5 x 10"10 unit/(pm 2-s)

A T -III

k (reaction)
0.0161 s"1
0.0283 s'1

5.94 x 10 8 pmol/(cm 2-s)

o2

4.02 s'1

constants (k). Figures 17 through 19 illustrate the concentration profiles o f TxA2,
reaction thrombin, and NO respectively. The plots are shown on a semi-logarithmic

55
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graph w ith m ultiple curves super-imposed on the same graph. Each curve represents a
different time during the transient analysis o f concentration as a function o f axial position
from the collagen surface. Proceeding in a bottom-to-top fashion, the curves represent
times o f 0.1, 0.25, 0.5,1, 5, and 60 seconds respectively.
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Figure 17 - TxA2 transport
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Figure 18 - Thrombin transport
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Figure 19 - NO transport
From inspection o f the three plots, high concentrations o f TxA2, thrombin, and
NO are isolated to w ithin the first 10 pm o f platelet aggregation. Sim ilar shapes o f the
concentration profiles were expected since the same model was used for all three cases;
however, each species transport characteristics are different due to individual diffusion
coefficients and reaction kinetics. Due to the assumption o f a constant surface flux for all
time, these models represent upper bounds for agonist and inhibitor concentrations, thus
creating a worse-case scenario w ith respect to coagulation. Since consumption exists in
the plasma, steady-state concentration profiles are bounded. The time to reach steady
state for TxA2, thrombin, and NO under the modeling assumptions were calculated to be
500,285, and 2 seconds respectively. Steady-state concentration profiles were
normalized for each o f the species and plotted in figure 20. Proceeding from left to right,
the profiles correspond to NO, thrombin, and TxA2.
The model demonstrates that maximal levels o f platelet-generated NO are reached
very quickly (w ithin 2 seconds) at the platelet surface, possibly playing a role in the local
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Figure 20 - Normalized steady-state concentration profiles of TxA2,
thrombin, and NO
suppression o f coagulation. However, as time progresses on the order o f minutes,
increasing levels o f TxA2 and thrombin begin to reach their maximum concentrations
thereby increasing the spatial extent o f agonists at critical concentrations.

3.1.2 A gonist Release M odel
The parameters used as constants for the serotonin and ADP transport models are
listed in table 6. It is assumed that platelets are uniform ly distributed across the collagen
surface in a monolayer fashion and that their granular contents are expelled instantly
upon activation by collagen. The value mo represents the amount o f agonist released
from the adhered platelets per square surface area. Figures 21 and 22 illustrate the
concentration profiles o f serotonin and ADP transport respectively. The plots are shown
super-imposed on the same graph. Each curve represents a different time during the
transient analysis o f concentration as a function o f axial position. Proceeding in a top-tobottom manner, the curves represent times o f 0 .1,0.5,1.0,1.5, 2.0, 5.0, and 10.0 seconds
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Table 6 - Model parameters for agonist release model
Species

Dab (cm2/s)
Serotonin 3.45 x KT6
ADP
2.57 x 10'6

Amount per platelet
0.3 x 10*" nmol
3.0 x 1 0 '" fim ol

mo (calculated)
7.16 x 10'13 |am ol/|im 2
7.16 x 10 '12 |4mol/(am2
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Figure 21 - Serotonin transport
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Figure 22 - ADP transport
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respectively.
Since serotonin and ADP are released and not continuously generated, surface
concentrations do not increase w ith time. These species are not homogeneously
consumed in the plasma, but the concentration profiles decrease in an exponential manner
w ith distance from the adhered platelets. Concentration profiles asymptotically approach
zero as distance increases to infin ity. As shown in the figures representing ADP and
serotonin transport, sub-micromolar concentrations are achieved before 100 microns.
According to the model, maximum agonist concentrations are found at the surface o f
adhered platelets. As time increases, these surface concentrations also decay in an
exponential fashion. More specifically, serotonin and ADP surface concentrations are
75% o f their in itia l maximum value at 2 and 0.18 seconds respectively. F ifty percent is
achieved at 4 and 0.4 seconds, 25% at 16 and 1.62 seconds, and 5% at 400 and 40
seconds respectively. Although the diffusion coefficients for serotonin and ADP are on
the same order o f magnitude, differences in their concentration profiles are attributed to
amount o f agonist release per platelet. The molar amount o f dense granule serotonin is
ten times less than dense granule ADP concentration. In vivo, it is possible for increased
ADP concentrations due to erythrocyte ADP liberation 32. Results o f the release model
for serotonin give support to the hypothesis that local serotonin concentrations are too
low in magnitude for platelet activation, and it may act to potentiate ADP and thrombin
activation 27.
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3.2 Serotonin Sensor D evelopm ent
The electrode fabrication process yielded excellent results w ith respect to cost,
production rate, and reproducibility. Ease o f construction allowed fresh electrodes for
each experiment performed. The rate-lim iting step during the entire fabrication process
was the overnight tip immersion in NaOH to remove excess beeswax, which took an
average o f eight hours to complete. Before saponification, it is possible to fabricate
twenty-five electrodes w ithin an hour. Initial starting costs are moderately high due to
the purchase o f medical grade carbon fibers; however, several thousand electrodes can be
made from the purchased spool. Additional hardware costs such as copper wire,
beeswax, silver epoxy, and glass capillaries are minimal.
Through empirical observation, electrodes stored dry in a dust-free environment
possessed a longer shelf life than those stored immersed in distilled water. When stored
in water for a long period o f time, reduced sensitivity is observed, perhaps due to
microbial growth fouling the sensor’s carbon surface. Before calibration, microscopic
analysis in the light field was performed to ensure proper tip sealing w ith beeswax, verify
the proper number o f fibers comprising the tip, scan the electrode shank for any cracks
w ithin the glass capillary, and ensure continuity between the carbon fiber and copper
conductor. Figures 23 through 25 show the various parts o f a typical sensor developed
for this research project.
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Figure 23 - Carbon fiber tip of sensor made of two fibers (lOOx)

Figure 24 - Sealed neck of sensor with protruding fiber (40x)

Figure 25 - Interface of carbon fibers with copper conductor (40x)
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3.3 Sensor Calibration
3.3.1 Sensor Detection Limits
Calibration range for the serotonin sensor was based on the detection lim its
observed in the laboratory. In the literature, it was reported that carbon fiber electrodes
using DPV could achieve detection lim its in the nanomolar range (parts per b illio n ). O f
course this value is dependent upon electrode size and electrochemical properties o f the
species o f interest. Therefore a simple test was performed to establish a lower detection
lim it for the probe. A serotonin standard was made so that injection o f one aliquot in an
electrochemical cell w ith PBS produced a final concentration o f 1 nM. DPV scans were
performed for each aliquot added, and it was discovered, on average, that a concentration
o f 4 nM was the smallest detectable amount o f serotonin that could be distinguished from
the background Gaussian noise o f the current signal. Figure 26 illustrates a current
deflection caused by a 4 and 144 nM serotonin standard.
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Figure 26 - Deflections in DPV scans corresponding to 4 and 144 nM serotonin
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The region around 550 mV represents the change in baseline due to the oxidation o f both
serotonin levels on the carbon surface. Actual oxidation potential o f serotonin is probe
dependent; however, it was observed to always be in range o f 550 ± 50 mV. This
potential is w ithin the range published in the literature. For example, B ull et al. found the
oxidation potential for serotonin to take place at 579 mV 56. it appears that the current
produced from the 4 nM standard is larger than the 100 pA noise magnitude. Any probe
that failed to detect the 4 nM serotonin control during the calibration process was
discarded.
A detection lim it for the maximal amount o f serotonin was also found. In theory,
it is usually assumed that the analyte concentration at the probe’s catalytic surface is zero
due to immediate species oxidation. This assumption is valid for low concentration
levels, but at elevated concentrations, the flux o f analyte to the sensing element occurs
faster than the oxidation reaction. Therefore, analyte begins to accumulate on the tip
resulting in a plateau o f current despite increased concentrations. To find the upper
boundary for serotonin detection, additional serotonin aliquots were administered to the
cell until no change in current was detected when compared w ith the previous scan. It
was found that the maximum detectable lim it o f serotonin concentration on average was
300 nM. Figure 27 illustrates a scatter plot o f typical sensor calibration data. A fter 300
nM there is a slight decrease in current value, indicating an upper bound detection lim it.

3.3.2 Pow er Law Regression o f C alibration Data
Upon completion o f probe calibrations and data processing in Labview, scatter
plots o f current versus serotonin concentration (mean ± stdev) were generated in Excel.
A t first glance, the calibration data followed a linear trend w ith a high degree o f
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Figure 27 - Example upper saturation limit from calibration
correlation. However, closer inspection o f the plot showed that the linear trend was only
isolated only to the high concentration values w ith excellent agreement. The regions o f
low concentration revealed nonlinear trends. When the regressional analysis was
performed using a power law regression, good agreement w ith a high degree o f
correlation was achieved in both the low and high concentration values. Therefore,
power law regression was used to mathematically model the electrode’s calibration data.
Figure 28 shows a typical calibration curve for serotonin, and Table 7 compares the
correlation (R2) differences between a linear and power law regression for the calibration
data o f seven independent electrodes.
It is also proper to note here that the standard deviations o f the repeated measures
increased w ith increasing serotonin concentrations (as seen in Figure 28). On average,
m inimal variance w ithin the electrode calibrations was seen at the m inim al detection lim it
o f 4 nM. As serotonin concentration approached the upper detection lim it, variance

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

66

increased. This upper lim it is believed to be attributed to the current plateau caused by
the accumulation o f serotonin at the electrode’s surface.
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Figure 28 - Example of power law for an electrode calibration
Table 7 - Comparison between linear and power law correlation values
Electrode
BR8
BR9
BR6
BE4
BE8

Linear

0.7899

Power
0.9821
0.9999
0.9874
0.9049
0.8760

BE9

0.9858

0.9939

3.4

0.9785
0.9849
0.9415
0.8531

Testing o f Electrode in Blood

3.4.1 Uric Acid Interference
Since all electrodes were calibrated in PBS, interfering species were not present.
When an attempt was made to interface the electrodes in bovine blood to achieve a
baseline DPV, the effects o f interfering species became present. An analysis and
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literature search determined what was interfering electrochemically w ith the electrode at
a sim ilar potential as serotonin. Table 8 depicts possible interfering species that are
electrochemically active and present in the plasma. Uric acid proved to be a viable
candidate due its large concentration in mammalian plasma.
Testing was performed w ith 200 pM uric acid dissolved in PBS, and upon
conclusion o f the baseline DPV scan; U A was oxidizing at average potential o f 544 ± 5
mV. This potential was almost exactly the same as the potential for serotonin. Since
DPV requires at least a 50 mV potential to discriminate between m ultiple species, UA
was eliminated through the use o f the enzyme uricase. Uricase is an enzyme that
converts U A to allantoin, which is electrochemically inert 57. When a final PBS solution
containing 150 pM UA and 200 nM serotonin was created, the serotonin signal could not
be differentiated from UA. Upon addition o f 0.2 units o f uricase, U A interference was
suppressed and the signal due to serotonin was resolved. This result im plied that uricase
does not interfere w ith serotonin measurements.
It was observed that U A returns a higher current value than serotonin at
physiological concentration. For example, a 200 nM serotonin concentration would
cause a 5 nA deflection from baseline, whereas a 150 pM UA would cause a 70 nA
deflection. Since each molecule is sim ilar in formula weight, differences must arise in
the oxidation reaction.

3.4.2 Testing in Blood Variants
W ith uricase to inhibit UA, blood variants consisting o f whole blood, PPP, and
dilute PRP were tested w ith known quantities o f serotonin. When increased amounts o f
serotonin were added to whole blood and PPP, change in current due to serotonin
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Table 8 - Possible interferences: the means and expected ranges of readily
oxidizable, secretory products in adult human plasma

BIOCHEMICAI,
Glucose

MEAN

RANGE

PACE*

5.52mM

4.55-6.50 mM

605

Glutathion

925.

pM

703-1082pM

573 (only in erythrocytes)

Urate

289.

pM

124-454 pM

577

Glutamate

58.5 pM

17-118 pM

574

Tyrosine

50.2 pM

35.9-62.3 pM

574

Tryptophan

48.0 pM

25.0-73.0 pM

574

Cysteine

41.7 pM

27.1-79.4 pM

574

Ascorbate

27.0 pM

11.1-49.7 pM

611

Nitrite

174. nM

0-348 nM

564

Acetylcholine

87.6 nM

0-252 nM

575

Serotonin

73.8 nM

5.7-142 nM

575

Dopamine

9.6 nM

±2.9 nM

733

Norepinephrine

1.8 nM

±0.4 nM

733

Epinephrine

0.33nM

±0.28 nM

733

Peroxide

-p M

Sup eroxide

~pM

(whole blood)

*Geigy Scientific Tables 7ed, K. Diem, C. Lentner eds., Cibe-Geigy Ltd. Basle, S w it (1970)
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oxidation was not seen. Instead, poisoning o f the electrode was observed. Since the tip
is held at positive potentials and most o f blood colloidal species o f the blood and plasma
are negatively charged, it is possible that the electrode tip became contaminated with
blood proteins creating a diffusion barrier to serotonin. The dilute PRP has the same
platelet concentration as whole blood, but about one-tenth the protein content. Signals
due to serotonin oxidation were observed during calibration w ith dilute PRP. Scatter
plots were sim ilar to the ones obtained from calibration in PBS. Therefore, it was
concluded that serotonin measurements could be made in dilute PRP without interference
due to sensor fouling.

3.5 Static Study to M easure Serotonin Release
from Platelets
3.5.1 Evaluation o f Fibrillar Collagen Film
The fib rilla r collagen coating o f the tissue culture dishes was the sole activator o f
platelet a ctivity in the static study. It is known that platelets are activated by and adhere
to fib rilla r collagen. Therefore, it was pertinent to determine histologically i f the
collagen surface was fib rilla r or not. Figure 29 is a collagen image taken from a tissue
culture dish prepared w ith fib rilla r collagen as outlined in the methods section. Collagen
stains pink when eosin is used as the staining agent, and fib rilla r formations are easily
seen in the background o f the image. This image was compared w ith a microscopic
illustration o f collagen provided in a histology laboratory manual, and the microscopic
features matched.
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3,5.2 M easurem ents in D ilute PRP
For each tria l performed (four in all), a fresh electrode was used. Data obtained
from the electrodes was mapped back to a serotonin concentration through the use o f

. •* .

• • ' CT « Ml .

, L.

—

•*

Figure 29 - Fibrillar collagen coating in tissue culture dish (lOOx)
Equation 13. Regression constants, A and C, are specific for each electrode used. Table
9 below presents the serotonin concentrations as a function trial number and experiment
type. From inspection o f the concentration values listed in Table 9, many o f the values
are below the 4 nM detection lim it for serotonin. These values are considered to be in the
noise region o f the sensor and they represent current levels that are below 100 pA. Since
the background noise is Gaussian and random in nature, it is present in all measurements
made from the sensor. I f these values below 4 nM were forced to take on a value o f zero,
the average magnitude o f the random noise would have to be subtracted from the
remaining measurements as w ell. Keeping the sub-threshold values does not violate that
statistical analysis.
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Table 9 - Serotonin data from static study in dilute PRP
Exp 1 (nM) Exp 2 (nM) Exp 3 (nM) Exp 4 (nM)
1.77
10.10
6.24
17.18
Trial 1
3.15
19.65
3.96
48.82
3.00
17.12
0.68
12.51
8.51
19.66
1.15
14.72
Trial 2
5.07
14.96
0.38
7.81
5.07
13.93
2.52
3.76
2.86
16.57
0.49
3.86
Trial 3
0.51
24.87
2.17
14.49
1.56
17.50
2.82
16.93
1.95
5.13
3.52
11.91
Trial 4
1.86
9.25
1.50
6.92
1.31
4.07
1.17
8.35

3,5.2.1

Single Factor ANOVA. In itia lly a single factor AN O VA was

performed on the data w ith experiment type designated as the treatment levels. Thus,
four treatments are present. The different treatments/experiments are: (1) no collagen
w ith dilute PRP (2) collagen w ith dilute PRP (3) no collagen w ith dilute PRP and LN M M A and (4) collagen w ith dilute PRP and L-N M M A . The single factor AN O VA w ill
indicate i f any o f the means are statistically different. I f so, a m ultiple comparison test
w ill show the treatment levels that are statistically different. Tukey’s m ultiple
comparison test was chosen because it has a type I error rate o f a for all pair wise
comparisons on an experiment wise basis 58. Table 10 shows the single factor ANO VA
results. The AN O VA indicates that the treatment means are statistically different w ith a
P < 0.0001.
In performing the Tukey test, the test statistic (7) was calculated by equation 14.

r = ,„ ( a ,/) S i,

Eq. 14

Where q ja ,f) is the studentized range statistic w ith a treatments a n d /is the number o f
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Table 10 - ANVOA table for single factor experiment with four treatment levels
ANO VA: Single Factor
SUM M ARY
Groups
Exp I
Exp2
Exp3
Exp4

Count
12
12
12
12

Sum
Average Variance
36.617
4.904
3.051
38.57
172.815 14.401
2.989
26.600
2.216
142.387
167.264 13.938

AN O VA
Source o f Variation
SS
Between Groups
1602.393
W ithin Groups
2077.422

df
3
44

Total

47

3679.815

MS
534.131
47.214

F
11.312

P-value
1.26E-05

F crit
2.816

degrees o f freedom for error. S is the standard error for each average calculated by
Equation IS.

T is calculated to be 7.518, im plying that two means are significantly different i f the
absolute value o f their sample differences exceeds this value. From inspection o f the
sample means based on treatment levels, comparisons o f experiments 1 to 2, 2 to 3, 1 to
4, and 3 to 4 show statistical differences.
From this single factor analysis it can be concluded that serotonin concentrations
are elevated in the presence o f fib rilla r collagen when compared w ith the absence o f
collagen. Presence o f the NOS inhibitor, L-N M M A , did not have a statistical
significance when compared across experiments w ith fib rilla r collagen, which lacked LN M M A . It can be inferred from this analysis that a statistically significant change in
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serotonin concentration, resulting from platelet activation by collagen, could not be
detected when compared in presence and absence o f the NOS inhibitor L-N M M A .

3.5.2.2

Tw o-Factor A N O V A. Since each experiment was composed o f

four independent trials w ith three repeated measures each, a two-factor AN O VA was run
to guard against an inflated error mean square. The two factors were experiment type and
trial. Another advantage to this analysis was performance o f an interaction analysis
between experiment type and trial. When a comparison is made between the single and
two factor AN O VA tables, the error mean square was reduced from 47.2 to 34.7, which
is a 26.5% reduction. The results are sim ilar to the single factor AN O VA since the
treatment means are s till experimentally different w ith a P < 0.0001. Table 11 shows the
obtained results. Information is now

Table 11 - Two-factor ANOVA results (factors are experiment and trial)
Two-factor
AN O VA
Source o f Variation
Trial
Experiment
Interaction
W ithin

SS
319.254
1602.393
646.685
1111.482

df
3
3
9
32

Total

3679.815

47

MS
106.418
534.131
71.854
34.734

F
3.064
15.378
2.069

P-value
0.042
2.268E-06
0.063

obtained about the local repeated measures as w ell as interaction between trials and
treatment types. Figure 30 is a plot o f the interaction between trials and experiment
types. This interaction is m arginally significant (P = 0.063 in table 11).
Tukey test was again used to compare among experiment means over trials. For
this m ultiple comparison analysis, a T value o f 13.00 was calculated. Statistical
differences were shown for tria l 1 between experiments 1 and 2, 1 and 4, and fin a lly
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F crit
2.901
2.901
2.188
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Figure 30 - Interaction analysis for the two-factor AN O VA
3 and 4. For trial 2, differences were shown only for experiments 2 and 3. For trial 3,
differences were shown for experiments 1 and 2, followed by experiments 2 and 3. In
trial 4, no differences between experimental means were observed. Some interaction
does occur across the trials performed for each experiment; however, as seen below
conclusions drawn about the marginal effects across the different experimental
parameters remain the same as those drawn from the single factor AVO NA. It is possible
that interaction between trials and experiment type is a result o f tip fouling from the three
repeated measures taken consecutively.
A final comparison between experiment types was conducted using the marginal
means o f experiment type. This comparison was performed to see i f the same conclusion
could be drawn about the experiment as in the single factor ANO VA. Tukey test was
again used and a T value o f 6.S0 was calculated. Statistical differences were observed for
experiment groups 1 and 2,1 and 4 ,2 and 3, and fin a lly 3 and 4. These results exactly
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match those o f the single factor AN O VA, however the two-factor A N O V A had a reduced
the error mean square value by 26.5 percent.

3.5.3 H istological Analysis o f Adhered Platelets
In itia l verification o f adhered platelets was performed by finding an aggregate at a
magnification o f 400 in the U V field, followed by scale measurements o f the same
aggregate in the light field. A magnification o f 400 proved to be sufficient resolution to
measure individual particle sizes o f the resulting aggregate. Since platelets have an
average diameter o f 2 to 3 microns, a magnification o f 400 is powerful enough to resolve
individual platelets. Figure 31 represents the morphology and composition o f a typical

Figure 31 - A typical aggregate showing individual platelets with a 10 pm scale
(400x)
platelet aggregate at 400x. The aggregate shown in figure 30 is irregular in shape and has
a width and height o f approximately 30 pm and is typical o f thrombus size reported in the
literature 59. A scale superimposed on the figure has divisions o f 10 pm. Individual
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platelets can be resolved and they appear as small, light-colored areas scattered across the
thrombus surface.
Tissue culture dishes were randomly chosen from the four experimental
conditions. Each dish was fixated w ith form alin and stained w ith acridine orange as
described before. Acridine orange was chosen as the fluorescent stain since it is selective
to platelet cytoplasm, thus, allow ing the entire aggregation o f platelets to fluoresce under
ultraviolet light. When dishes from experiments 1 and 3 were observed in both the light
and UV fields, platelet aggregates were not present. Examination o f dishes from
experiments 2 and 4 revealed platelets aggregates adhered to the collagen surface
scattered throughout the dishes. Figures 32 and 33 represent microscopic images o f

Figure 32 - Adhered platelet aggregates on collagen (40x from experiment 2)
platelet aggregates at a magnification o f 40 in the U V field for experiments 2 and 4
respectively.
Five independent random measures for each dish were obtained for the number o f
aggregates and percent surface coverage o f the 40x and lOOx field. Experimental data for
the five random measures is presented in Tables 12 and 13 below.
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Figure 33 - Adhered platelet aggregates on collagen (40x from experiment 4)
Table 12 - Data from platelet count on collagen surface for 40x and lOOx (N = 5)
Count of Platelet Aggregates on Collagen
Surface
Measure
40x Field
lOOx Field
Number
Exp 2 Exp 4 Exp 2 Exp 4
7
1
50
10
36
6
2
42
13
38
19
3
34
34
12
4
40
10
11
49
5
8
40
47
8
P = 0.92
P = 0.74
Results o f the tw o-tail t-tests performed between experiments 2 and 4 for
magnifications o f 40 (P = 0.92) and 100 (P = 0.74) showed no statistical significance for
the number o f adhered platelet aggregates. Examination o f the total surface area covered
by platelet aggregates was also found to be insignificant when compared at
magnifications o f 40 (P = 0.10) and 100 (P = 0.66). The magnitudes o f aggregate number
and size appear to be independent o f NOS inhibition. Results from histological analysis
support the conclusions obtained from the electrochemical measurement o f serotonin.
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Table 13 - Data from percent surface area coverage by platelets on collagen surface
for 40x and lOOx (N = 5)
% Surface Area Occupied by Platelet
Aggregates on Collagen Surface
40x Field
Measure
lOOx Field
Number
Exp 2 Exp 4 Exp 2 Exp 4
3.47
2.41
1
2.19
3.52
1.96
2 .2 0
2
1.96
5.38
2 .1 2
1.96
4.80
3
3.31
3.23
4
2.55
1.90
3.40
1.95
2.29
3.16
5
1.93
P = 0 .1 0
P = 0 .6 6
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CHAPTER 4

DISCUSSIO N

4.1 M athem atical Models
Serotonin, released from platelet dense granules upon activation, is believed to be
influenced by platelet-derived NO. Due to the short half-life o f NO observed at
physiological levels, direct measurement o f NO in real-time is non-trivial. Therefore, it
was hypothesized that platelet-derived NO may modulate the release o f platelet granule
contents. Due to its stability and favorable electrochemical properties, serotonin was
chosen as the species for direct measurement. Experiments performed in this dissertation
were designed ultimately to measure serotonin directly in dilute plasma in the presence
and absence o f the NOS inhibitor L-N M M A . Preliminary modeling o f platelet agonists
and inhibitors, through static diffusion simulations, provided insight about the transport
characteristics and surface concentrations o f serotonin, NO, TxA2, and thrombin.
Knowing the surface concentrations and chemical kinetics resulting from thrombus
formation is critical in understanding atherosclerosis. Mathematical models supported by
electrochemical measurements are only validated through direct histological evidence o f
platelet adherence.
The mathematical models represent upper bounds on platelet-derived agonist and
inhibitor concentrations. Assumptions made before model development allowed for
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analytical solutions to be obtained, but modeling o f the more complicated conditions
found in vivo and vitro would require numerical solutions. For example, ADP and
serotonin release from platelets occurs over an extended time as the platelets adhere and
form aggregates. The model assumes granule release happens instantly from the entire
thrombus, but this type o f release does not occur in vivo or in vitro. Inspection o f
adhered platelets on collagen in this study supports the idea that thrombus formation is a
diffuse process and does not progress uniform ly even when highly thrombogenic surfaces
such as collagen are exposed during experimentation. Although the models developed
for this project are idealized cases, pertinent inform ation w ith respect to the transient
development o f critical agonist and inhibitor surface concentrations was ascertained.
These models assumed a uniform platelet distribution across the entire collagen surface.
It was not desired to predict the time course o f or platelet adhesion and aggregation
processes, due to complex interactions between agonists and inhibitors 24,25
Generation o f platelet-derived agonists and inhibitors is assumed to progress in a
constant fashion, only hindered by homogeneous reactions in the plasma. Reactions in
the sim ulation are assumed to depend only upon concentration o f the species modeled via
first-order kinetics. For example, 0 2 * concentration is relatively constant in the body, but
it may be variable in close proxim ity to a platelet thrombus. NO is believed to be the rate
lim iting species in the reaction w ith O 2 ', being kept at low concentrations and locally
lim ited. But i f

02

* is quickly removed locally, NO concentrations may be enhanced at

greater distances from the thrombus source.
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4.2 Experim ental Evaluations
The mathematical model shows an elevated level o f serotonin close to the
collagen surface

(12

pM after

1

second), but the electrochemical measurements in the

presence o f collagen revealed only an average concentration level o f 14 nM. This value
is several orders o f magnitude lower than the mathematical model shows. The sensor had
an effective height o f

1

mm; therefore, all measurements made are space averaged over

the sensor’s surface area. The concentration profile o f the model indicates a maximum
concentration level w ithin the first

10

microns, which sharply attenuates between

10

and

100 microns. Therefore, a low-level serotonin concentration was expected at the
effective distance o f the sensing element. When the experiment was performed in the
presence o f L-N M M A (experiment 4), an elevated level o f serotonin could not be
detected statistically as hypothesized. This result is not interpreted as no effect from NO,
but i f an effect was present it was not detectable w ith the carbon fiber sensors designed
for this research.
Microscopic inspection o f the platelet aggregates adhered to collagen show a nonuniform aggregation o f platelets. The mathematical model assumes uniform adherence in
monolayer fashion, w ith every square area releasing serotonin in itia lly . From the model,
it can be concluded that serotonin concentrations are locally elevated at the origin o f the
aggregate. Due to the diffuse nature o f the aggregates in vitro, serotonin concentration
must be a function o f sensor placement location on the surface area. It has been
discussed above that the height above the dish is also a factor. Stronger serotonin
concentrations may be observed i f the probe were placed directly on the surface o f a
platelet aggregate. In the experiments performed, the probe was randomly positioned and
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lowered onto the dish. Perhaps under microscopic observance, particular platelet
aggregates could be targeted for probe placement. Results from the electrochemical
measurements and microscopy showed sim ilar conclusions. In this context, it appears
that NO is not lim iting or hindering thrombus formation in vitro. It has been extensively
reported in the literature that basal levels o f NO are continuously released from platelets
w ith elevated levels directly related to activation, adhesion, and aggregation 5,35,60,61
There are some possibilities o f why, NO did not produce a statistically measurable effect
in the study.
It is possible the inhibitory function o f platelet-derived NO is synergetic w ith
prostacyclin (PGI2 ), a compound produced from arachidonate metabolism in the
endothelial and smooth muscle cells o f blood vessels 34. PGI2 is a potent vasodilator and
inhibitor o f platelet aggregation. Figure 34 illustrates the mechanism o f platelet
inhibition by PGI2 . Platelet membranes contain a receptor for PGI2 coupled to adenylate

PGI
receptor

platelet membrane

sub-unit
^adenylate
cyclase

ATP

Ca‘

cAMP

Figure 34 - Platelet inhibition by PGI2
cyclase through a stimulatory subunit. When PGI2 reacts w ith its receptor, on the platelet
membrane, adenylate cyclase is activated and rapidly converts intracellular adenosine
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triphosphate (ATP) to cyclic adenosine monophosphate (cAM P) 53. \ rise in intra
platelet cAM P concentration causes a cytosolic Ca2+ shift to a membrane-bound form,
resulting in a decrease in free cytosolic Ca2+ concentration 53. This mechanism is sim ilar
to platelet inhibition by NO. For NO inhibition o f platelet function, cumulative evidence
suggests that the major mechanism is through activation o f platelet soluble guanylate
cyclase to increase levels o f cGMP 35. Although both are sim ilar in function, the effect
o f PGI2 is more pronounced due to its longer h a lf-life than NO.
Interestingly, T.xA2 is also derived from arachidonate, but it functions as an
activator o f platelet activity rather than an inhibitor (Figure 35). Once platelet adhesion

Stood

■--------------------- P Q H ,
I Thtom ooM no
|
synV w tftM
"■*'*» T X A f

/ P ro m o ** \ I
\ a b ro g a tio n / J
TX Bj
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\c A M P )

j

S
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Figure 35 - Model of PGI2 and TxA2 production and effects
(From Gorman, 1979
on the damaged endothelium occurs, PGI2 is synthesized to inhibit further aggregation.
The combined effect between PGI2 and NO m ight produce critical inhibitor
concentrations locally, which are required for platelet inhibition. I f the idea o f synergism
between PGI2 and NO is correct, then the absence o f one could potentially lead to a
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m inim al effect w ith respect to platelet inhibition. The experiments performed in this
dissertation were controlled to only contain platelets in diluted PRP. Therefore, PGI2 was
not present in the study, and NO was assumed to be the main inhibitory agent available.
Another possibility o f no measurable effect could be attributed to the static dish
containing dilute plasma. Under static conditions, the same population o f platelets is
exposed to the collagen surface for the duration o f the experiment. In vivo , blood flow
through the vasculature continuously circulates the entire platelet population over time.
I f a vessel injury were present, thus initiating platelet activation and adhesion, fresh
platelets would be exposed to the injury site continuously until the wound heals.
Continuous transport o f platelets to the injury could result in a high platelet density with
increased surface concentrations o f platelet-derived agonists and inhibitors. In a
convective flow situation, the axial velocity component appears to be the dominant role
o f species transport. This assumption is true at distances far from the vessel w all, but it
has been shown that large concentration gradients exist at the vessel w all due to
decreased velocities as a result o f the parabolic velocity profile 48,63 platelet aggregates
in convective studies have been reported to have elliptical bases w ith the major axis
parallel to the direction o f flow 59. it is assumed in a convective flow situation, there
could be an increased surface concentration o f platelet agonists and inhibitors allowing a
measurable effect o f NO function.

4.3 Serotonin M easurem ents and Data A nalysis
In application o f the serotonin sensor to blood components, many experimental
difficulties had to be overcome. D ifficultie s include sensitivity, noise, tip fouling, and
interfering species. From incremental laboratory measurements, detection lim its for the
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sensor on average were 4 to 300 nM. This range is in good agreement w ith serotonin
levels found physiologically, which have been published to be between 5.7 and 178 nM
64. However, the sensitivity o f the probe is a function o f the instrumentation used to
am plify and condition the signal. From baseline recordings in PBS without any
electrochemically active species, it was shown that the potentiostat had random
fluctuations o f 100 pA magnitude. Discrete fluctuations such as these are attributed to
machine noise as w ell as quantization error from the digital to analog conversion process.
However, probe sensitivity, w ith current instrumentation, was found to be approximately
4 nM. This response was represented by a 100 pA deflection from the baseline
recording. For the in vitro studies performed, measured values o f serotonin were at or
moderately above baseline indicating that we were close to the noise region o f the sensor.
A Faraday cage was used to see i f the noise source was environmental, but no change in
sensitivity or noise level was observed when implemented, therefore indicating possible
noise w ithin the sensor (resistor noise). The final sensor developed proved worthy o f
measuring low levels o f serotonin (4 to 300 nM ) w ith a sensitivity o f 4 nM.
Another major problem associated w ith in vitro measurements was tip fouling. It
is believed that tip fouling occurs due to electrostatic attraction between the positive
potential o f the working electrode and the negatively charged peptides in plasma 65. An
approach to guard against tip fouling is to coat the carbon fiber surface w ith Nafion, a
perfluorosulfonated derivative o f Teflon that acts as an ion-exchange polymer whose
film s are highly permeable to cations but almost impermeable to anions 6 6 . when this
was applied to the sensor during calibration processes, sensitivity to serotonin was
attenuated from 4 nM to approximately 10 nM. Since Nafion is a coating, it creates a

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

86

diffusion barrier on the sensing element; therefore, as coating thickness increases,
sensitivity decreases. Drs. Jones and Patton from Louisiana Tech University have
indicated that serotonin might be slightly negative when dissolved in solution at
physiological pH. Therefore, Nafion coating due to electrostatic interaction might retard
serotonin transport to the carbon surface resulting in signal attenuation. Therefore, other
steps were taken to decrease tip fouling.
Since the experiments were concerned only w ith blood platelets at physiological
concentrations, it was desired to extract different blood components to isolate the source
o f fouling. It is known that peptides interfere, but the researcher was unsure about
formed elements such as erythrocytes. PRP and PPP were tested separately, and the same
degree o f tip fouling was observed. It was seen in the literature that concentrated platelet
suspensions are used for platelet function studies 67-69 Acting upon this insight we
generated PRP, w ith standard protocols, and then re-suspended the PRP back to the
original blood volume. On average 100 mL o f blood returned 10 mL o f PRP, therefore
the interfering peptide and protein contents were diluted by 90% and normal platelet
density was achieved. When tests were performed on dilute PRP, there was a strong
interference due to uric acid at almost the same potential as serotonin. Addition o f
uricase enzyme completely eliminated the interference, and subsequent serotonin
calibrations were performed w ith sim ilar results as obtained in PBS.
Concerning the processing o f DPV data in Labview, an interpolating
polynomial was needed to model the deflection o f the oxidation current. Due to the noise
in the signal, error would be introduced into the analysis i f the minim um value o f the
peak was chosen as opposed to the minimum o f the interpolating function. Since signal
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noise was assumed to be a random fluctuation, then the interpolating polynom ial would
return an average value o f the signal at the point o f interest. It was found that signals
representing low concentrations had good agreement w ith a 3rd-order polynom ial, due to
its slight parabolic profile. However, as the concentration level increased, a 4th-order
polynom ial was needed for good agreement. This assumption did not represent a
problem because the shape o f the signal was approximately 4th-order. It is not advised to
increase the polynomial order, because o f large-scale oscillations in the resulting
interpolation. As the order o f an interpolating function increases, large oscillations occur
at sharp discontinuities in the data 70.

4.4 C oncluding Rem arks
In mammalian physiology, NO plays a role in the regulation o f vascular tone,
hemostasis, neuronal transmission, and cytostasis 60. Platelets secrete a batch o f agents
that promote coagulation, however they also produce NO, which has the opposite effect
o f other platelet-derived compounds. W ith respect to platelet function, it is well
documented that platelet-derived NO is partially involved in maintenance o f vascular
tone and platelet inhibition. From the research conducted in this project, many questions
have been postulated concerning the primary role o f NO in platelet function.
Since we did not detect a measurable difference in serotonin concentration due to
NOS inhibition, it does not mean that platelet function, prim arily dense granule release, is
unaffected by platelet-derived NO in vivo. It is possible that the role o f platelet generated
NO is enhanced by the possible synergism w ith PGI2 or endothelial-derived NO.
Inhibitory agents such as NO and PGI2 are synthesized and released into the circulation
through diffusive flux across a phospholipid membrane. Flux is defined as the product o f
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mass flow rate and surface area. Due to size differences between the platelet and
endothelium, the endothelium possesses more effective surface area than the platelets,
and hence more NO and PGI2 are released into the blood stream. This observance may
support the idea that the inhibitory role o f platelet NO is achieved through synergism
w ith endothelial derived PGI2 and NO.
In the past few years, it has been suggested that a prim ary role o f platelets w ithin
mammalian circulation is in the defense o f the host against invading foreign organisms.
Perhaps, in this situation, platelet-derived NO’s major function is in the role o f cytostasis
in wound healing. Under in vivo conditions, open wounds, such as breaks or tears in the
endothelium, are subject to bacterial infection. Hemostasis is initiated through platelet
transport to the site o f injury where activation, adhesion, and aggregation take place. As
the platelet-dense thrombus begins to grow, aggregated platelets are synthesizing NO.
From the mathematical transport model dealing w ith NO, surface concentrations can
surpass 5 nM. This model assumes a uniform monolayer o f adhered platelets. In vivo , it
is known that platelets adhere to each other in all directions during thrombus growth. It
might be possible for local NO concentration directly above the injury to be even higher
than on the surface o f the thrombus, thus providing the injury w ith the NO required to
inhibit bacterial invasion.
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4.5 R ecom m endations for Future Research
The completion o f this dissertation presented a number o f different questions that
need to be researched in order to determine the exact physiological role o f plateletderived NO. Questions presented were as follows:
1. Does PGI2 have a synergistic role w ith platelet-derived NO for inhibition o f
platelet function?
2. What effect does convection have on platelet deposition and dense granule
release?
3. Through micro-manufacturing techniques, can the serotonin sensor be fabricated
to resolve sub-nanomolar concentrations w ith a high degree o f sensitivity?
4. Can a sensor be fabricated to circumvent fouling and uric acid interference?
To resolve the effects o f PGI2 , a sim ilar experiment can be performed using some o f
the methods used in this project. Since PGh is exclusively made in the vessel wall,
performing a study w ith dilute PRP as in this project can control it 62. The follow ing
combinations would be tested w ith collagen again as the platelet activator and serotonin
would again be measured: (1) PGI2 in dilute PRP (2) PGI2 in dilute PRP w ith L-N M M A
(3) dilute PRP and (4) dilute PRP w ith L-N M M A . By performing this study, information
would be gained about the combined effects o f PGI2 and platelet NO.
Two types on convective studies can be performed. In itia lly, the collagen-coated dish
could be gently mixed using an orbital oscillator. The orbital motion would cause the
dilute PRP to gently m ix in the dish and thereby increase the convective transport o f
more platelets to the collagen surface fo r potential activation. I f platelet inhibition by NO
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is a function o f convective transport, an increase in serotonin concentration should result
w ith addition o f L-N M M A .
The second type o f convective study would involve an in vitro flow simulation.
The flow simulation would consist o f a silicon model w ith a straight-tube geometry
coated in the center w ith a segment o f collagen. A stepper motor driven syringe pump
would be used to force diluted PRP, w ith and without L-N M M A , through the model at a
constant Reynolds number. Incorporated w ithin the model, a serotonin sensor would be
placed directly next to the collagen surface. Figure 36 illustrates the proposed flow
model. Following the flow simulation, histological analysis on the collagen surface
would be performed as a means to support the DPV data.
Electrochemical

Robe

z'

Syringe
Pump

Reservoir
Bag
Flow Direction

Coated
Region

Clamp 1

Figure 36 - In vitro flow simulation apparatus
Through the use o f micro manufacturing technology, it might be possible to create
a carbon fiber-based electrode system w ith sub-micron surface area, high sensitivity, and
extensive linear range. It is believed that greater sensitivity could be achieved i f an
am plification system were connected directly to the sensing element. In the current
system used for signal conditioning and amplification, the three-electrode system is
connected to the potentiostat through a five-foot length cable. Since the electrode is
recording values on the order o f nanoamps, noise interference m ight be significant. I f the
signal was am plified w ith a gain o f only

1 0 4,

line loss and signal resolution would be
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increased. Sensitivity to sub-nanomolar levels would further assist in determining the
primary function o f platelet-derived nitric oxide.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX A
AG O NSIT AND IN H IBITO R G ENERA TIO N
M ODEL

92

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

93

Description o f M odel
A transient mathematical model to simulate the passive diffusion o f platelet generated
agonists and inhibitors was developed. Upon local activation by collagen (a strong
platelet activator), the platelet membrane catalyzes the production o f agonists and
inhibitors such as TxA2, thrombin, and NO.

M odeiing A ssum ptions
1.
2.
3.
4.
5.
6.
7.
8.

D iffusion model obeys Fick’s law
Constant densities and diffusion coefficients
Transient analysis in cylindrical coordinates (r,0, z) spaced averaged in r and 0
D iffusive transport dominate only in z direction
Consumption o f species in plasma through 1st order reactions rates (k)
Constant flux o f species occurring at collagen surface (K )
Negligible in itia l plasma concentration o f species
Species concentration approaches zero at an infinite distance from the surface

M athematical Description
Application o f the shell balance method under the guidelines o f the assumptions above,
the follow ing equation results:

at

=

oz'

- k C <<'•z)

Boundary and Initial Conditions
1.

The in itia l condition is represented by CA(0, z) = 0, which implies the
concentration o f species A for all o f length z is negligible for time less than or
equal to zero.

2. Boundary condition # 1 is represented by C(/,oo) = 0, which defines the
concentration o f species A for all time at an infinite distance is negligible.
3. Boundary condition # 2 states the surface flux o f species A was modeled as a
zero-order heterogeneous reaction (K ) as shown below.

dz

Solution to G overning Equation
Although the governing equation was homogeneous, the flux boundary condition was
heterogeneous. Therefore, the separation o f variables method for solving PDE’s was not
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applicable; therefore, a Laplace transform method was applied. The solution is described
in the follow ing steps.

Slep-1
Use the Laplace transform to transform the time variable [C\|(0 <-» F(.s)] in the governing
equations and boundary conditions. The governing PDE transforms to:
- CA(0, z) + sF(s; z) = D ab F ' ( s \ z ) - kF(s; z)
A fter substituting in the in itia l condition, the resulting ordinary differential equation
reduces to:

F '( s , z ) -

rs +k '
V

®AB

F (s,z) = 0

J

This is subject to the follow ing transformed boundary conditions:

F(s;oo) = 0 and F (s ; 0 ) =

K
sD ab

Step 2
The general solution to the resulting ordinary differential equation is:
i+ K p

_

s+K0

F (s;y) = Ae ' D'“ + Be ' °'a , where A and B are unknown constants.

Step.3
The constants A and B are now evaluated. When the infinite boundary condition is
substituted into the general solution, an infinite value results due to the positive infinite
exponent o f e. Since we know that a finite solution exists, B must be equal to zero.
Therefore, the general solution is now:

F(s',z) = Ae * 'D,a
To incorporate the remaining boundary condition, we must take the derivative o f F(s; z).

F {s',z) = - A
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A fter evaluation o f the surface boundary condition, we find that A = ------,------- ,---- =
S y ] D 1B y j s + k

The particular solution to this problem is
x+k

rv

,

\

K

&.ta

f (5;z) = ~
n r ~ r - tg
S y j D AB y j s + k

Step 4
The definition o f the inverse LaPlace transform ( L 1) is applied to transform the solution
from s domain to time (t). From inspection o f a table o f inverse LaPlace transforms, an
exact inverse transform does not exist, therefore properties o f the LaPlace transform can
be used to arrive at an integral solution. Application o f the inverse transform is shown
below:
s*k

C ,(r,z ) =

K

1g

V d ab

5

yjs+ k

In the LaPlace transform, division by powers o f s is the same as integration in the time
domain from 0 to t. The result o f this application is
s+k

c (( , , z ) = - J L { r
\ UAB

0

e ''D,“
yjs

+k

du

Next, the time shifting property was used: L~x\f{ s - a)] = e“'F (t)

du
\

U AB

0

V7

Now, the remaining part to be transformed is found in a standard transform table. The
transform identity is shown below:

o

e 41
yjm

, which returns the solution: CA(t, z) =

K

t

_I

tt
IyjxDw o

■*0,au I

=_
Vm
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D escription o f M odel
A transient mathematical model to simulate the passive diffusion o f agonists released
from platelets was developed. Upon local activation by collagen (a strong platelet
activator), the released alpha and dense granule contents. Released agonists o f interest
are serotonin and ADP.

M odeling Assum ptions
1.
2.
3.
4.
5.
6 .
7.
8.

D iffusion model obeys Fick’s law
Constant densities and diffusion coefficients
Transient analysis in cylindrical coordinates (r,0, z) spaced averaged in r and 0
D iffusive transport dominate only in z direction
No consumption o f species
Species are immediately released upon activation (No flux)
Negligible in itia l plasma concentration o f species
Species concentration approaches zero at an infinite distance from the surface

M athem atical Description
Application o f the shell balance method under the guidelines o f the assumptions above,
the follow ing equation results:

d C J t1z ) _ n
dt

d 2CA(t,z)
AB

d z2

Boundary and Initial Conditions
1. The in itia l condition is represented by CA(0,z) = S (z)m Q, which implies the
concentration o f species A is instantly released at the surface when time is zero.
mo represents the amount os species released per square area.
2. Boundary condition # 1 is represented by C(/,a>) = 0 , which defines the
concentration o f species A for all time at an infinite distance is negligible.
3. Boundary condition # 2 states the no flux condition for all time at the surface

Solution to Governing Equation
Although the governing equation was homogeneous, the flux boundary condition was
heterogeneous. Therefore, the separation o f variables method fo r solving PDE’s was not
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applicable; therefore, a Fourier transform method was applied. The solution is described
in the follow ing steps.

Step.1
Use the Fourier transform to transform the space variable [CA(z) <-> F(co)\ in the
governing equations and boundary conditions. The governing PDE transforms to

F'(t\o)) = D AB[ia)]2 F(t; a )
A fter sim plifying this relation and rearranging terms, we arrive at

F'(f,o)) + D aboj2F(r,co) = 0
This is subject to the follow ing transformed boundary conditions:

F(t; oo) = 0 and F (0, oj) = m0

Step 2
The general solution to the resulting ordinary differential equation is

F(t\o}) = C e 'D"“" , where C is an unknown constant.

Step 3
The constant C is now evaluated through use o f the surface boundary condition:
C = m0
The particular solution to this problem is

F(t;a>) = m0e 'D'‘a‘2'

Step 4
The definition o f the inverse Fourier transform (F*1) is applied to transform the solution
from o) domain to position (z). From inspection o f inverse Fourier transform tables, an
exact inverse transform was not found, therefore direct implementation o f the inverse
Fourier transform is required and is shown below.
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S im plification o f the above expression returns
D .at
2D , „ t

Evaluation o f the integral involves a variable transformation as follows:

Let

7

=

(O-

IZ

, then drj = ^ D ABtdo)

When the new variables are back substituted, the integral has the form
1
"r j
■- ------- Je '1' dr], which sim plifies to

V L ' a b * -«

K
*

Therefore, the solution to the agonist release model is CA(t,z) =

m
2y]xDMt
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